

## CURRICULUM VITAE

**DATE PREPARED** May, 2010

**Name** Gyongyi Szabo, MD, PhD

**Address** Department of Medicine/Division of Gastroenterology  
UMass Memorial Medical Center  
55 Lake Avenue North  
Room HA-223  
Worcester, MA 01655  
(508) 856-5275  
gyongyi.szabo@umassmed.edu

### **Personal Data**

**Place of Birth** Paszto, Hungary

**Citizenship** United States of America

### **Education:**

1984 MD, University Medical School Debrecen, Hungary

1991 PhD, Hungarian Academy of Sciences (Immunology/Medicine)

### **Postdoctoral Training:**

1984 Intern, Internal Medicine, University Medical School Debrecen, Hungary

1985 Postdoctoral Research Fellow, Health Institute, University of Innsbruck, Austria

1986 Postdoctoral Research Fellow, Department of Infectious Diseases, University Hospital, Leiden, The Netherlands

1986-1988 Research Associate, Department of Surgery and Molecular Genetics & Microbiology, University of Massachusetts Medical Center, United States of America

### **Clinical Training:**

1984-1985 Resident in Medicine, Department of Medicine, University Medical School Debrecen, Hungary

1994-1997 Intern/Resident in Medicine, University of Massachusetts Medical Center Worcester, MA

1997-2000 Fellow in Gastroenterology and Hepatology, Division of Digestive Diseases and Nutrition, University of Massachusetts Medical Center, Worcester, MA

### **Leadership Training:**

2008 AAMC Mid-Career Women Faculty Professional Development Seminar

2009-2010 Executive Leadership in Academic Medicine (ELAM)

### **Licensure and Certification:**

1984 Medical License, Hungarian Medical Association

1993-1995 ECFMG Certificate, USMLE Parts I and II

1994 Limited Medical License, Massachusetts

1995 USMLE Part III

1996 Massachusetts Medical License

1997-1998 Diplomate, American Board of Internal Medicine

2001 Diplomate, American Board of Medicine, Gastroenterology

### **Academic Appointments:**

1989-1992 Research Assistant Professor of Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, MA

1993-1995 Research Associate Professor, Dept of Surgery, and Immunology and Virology Program, Graduate School of Biomedical Sciences, UMass Medical School, Worcester, MA

- 1996-2000 Research Associate Professor, Department of Medicine, University of Massachusetts Medical School, Worcester, MA
- 2000- 2001 Associate Professor, Division of Gastroenterology, Department of Medicine, UMass Memorial Health Care/University of Massachusetts Medical School
- 2002-Present Professor of Medicine (Tenured, 2006), Division of Gastroenterology, Department of Medicine, University of Massachusetts Medical School
- 2008-Present Associate Dean for Clinical and Translational Sciences, University of Massachusetts Medical School
- 2009-Present Director, MD/PhD Program, UMass Med School, Worcester, MA

#### **Hospital and Affiliated Institution Appointments:**

- 1984-1985 Resident in Medicine, Department of Medicine, University Medical School Debrecen, Hungary
- 1994-1997 Intern/Resident in Medicine, University of Massachusetts Medical Center  
Worcester, MA
- 1996-2001 Staff Physician, Marlborough Hospital, Marlborough, MA
- 1997-2000 Fellow in Gastroenterology and Hepatology, Division of Digestive Diseases and Nutrition, University of Massachusetts Medical Center, Worcester, MA
- 2000-Present Director, Hepatology and Liver Center, Division of Gastroenterology, UMass Memorial Health Care

#### **Major Visiting Appointments:**

- 11/85-02/86 Visiting Research Scientist, Department of Health, University of Innsbruck, Austria
- 03/86-10/86 Visiting Research Scientist, Department of Infectious Diseases, University Hospital Leiden, The Netherlands

#### **Administrative Appointments:**

- 1990-1995 Director of Leukocyte Biology Laboratory, Department of Surgery, University of Massachusetts Medical Center
- 2000-Present Director of Hepatology and Liver Center, UMass Memorial Health Care/University of Massachusetts Medical School
- 2004-Present Chief, Gastroenterology Research, UMass Memorial Health Care/University of Massachusetts Medical School
- 2005-2009 Associate Director, MD/PhD Program, University of Massachusetts Medical School
- 2007-2009 Director, Clinical/Translational Research Training for Medical Students, University of Massachusetts Medical School
- 2009-Present Director, MD/PhD Program, University of Massachusetts Medical School

#### **Leadership Experience:**

- 2007-2008 Research Task Force, University of Massachusetts Strategic Planning Initiative
- 2007-2008 Leadership and Faculty Development Task Force, University of Massachusetts Strategic Planning Initiative
- 2007-2008 Acting as a Single Enterprise Task Force, University of Massachusetts Medical School, UMass Memorial Strategic Planning Initiative
- 2007-2009 Chair, Scientific Council
- 2008-Present Curriculum Interpretation Initiative Project III (CIP III), Steering Committee
- 2008-2009 Faculty Program Committee for the New Campus Facility, University of Massachusetts Medical School
- 2009-Present Leadership Council, University of Massachusetts Medical School
- 2009-Present Co-Chair, Translate Discovery into Practice, Strategic Planning Implementation, University of Massachusetts Medical School
- 2009-Present Environmental Scanning Task Team Strategic Planning, UMass Memorial
- 2009-Present Sherman Center Planning Committee, University of Massachusetts Medical School
- 2009-Present Women's Leadership Committee, UMMS
- 2009-Present Faculty Forward Committee, UMMS

#### **ACADEMIC AND PROFESSIONAL DISTINCTIONS**

##### **Awards and Honors:**

- 1983, 1984 Award Winning Presentations, National Student Research Council, Hungary
- 1992 American Liver Foundation, Student Research Fellowship (student: Maria Puppolo) - Mentor
- 2000 Distinguished Lecturer, Hungarian Immunology Society
- 2001 Society for Leukocyte Biology  
Travel Award (Postdoc Fellow: Angela Dolganiuc, MD, PhD)
- 2003 AGA/GRD Best Abstract of the Year (Postdoctoral Fellow: Angela Dolganiuc, MD, PhD) - Mentor
- 2003 Society for Leukocyte Biology Travel Award (Postdoctoral Fellow: Laszlo Romics, MD) – Mentor
- 2003 AASLD Presidential Award Winning Poster
- 2004 Diploma of Honorary Membership and “Geza Hetenyi” Award, Hungarian Society of Gastroenterology
- 2004 Research Society of Alcoholism, Travel Award (Postdoctoral fellow: Shilpa Oak, PhD) - Mentor
- 2004 AASLD Travel Award, Immunovirology and the Liver (Postdoctoral fellow: Angela Dolganiuc, MD, PhD) -mentor
- 2004 AASLD Presidential Poster of Distinction
- 2004 Presidential Award Finalist and Travel Award, Society for Leukocyte Biology (Postdoctoral fellow: Angela Dolganiuc, MD, PhD) – Mentor
- 2005 “Doctor Honoris Causa,” Semmelweis University, Budapest, Hungary
- 2006-Present Advisory Board, Yale Liver Center
- 2007 National Commission for Digestive Diseases, Advisory Board Member
- 2008 Dean’s Special Lecture, Georgetown University, Washington, DC
- 2008 AASLD Travel Award, Hepatitis Single Topic Conference, (Serena Chang, GSBS PhD Program, Bharath Nath, GSBS MD/PhD Program) mentor
- 2009 External Advisory Board Member, NIAAA, NIH
- 2009 “Women in Science and Health Achievement Award” University of Massachusetts Medical School
- 2009 Fellow in the 2009-2010 Class of the Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM) Program for Women
- 2009 Kelsey Family Named Professor, Division of Gastroenterology and Hepatology at the Mayo Clinic

#### **Editorial Boards:**

- 1992-Present Ad Hoc Reviewer:
- AIDS Research and Human Retroviruses
  - Alcohol
  - Alcoholism: Clinical and Experimental Research
  - American Journal of Gastroenterology
  - American Journal of Pathology
  - American Journal of Physiology
  - Biochemical Genetics
  - Circulation
  - Critical Care Medicine
  - European Journal of Pharmacology
  - European Journal of Hepatology
  - Free Radical Biology & Medicine
  - Gastroenterology
  - Hepatology
  - Infection and Immunity
  - International Journal of Immunopharmacology
  - Journal of Clinical Investigation
  - Journal of Hepatology
  - Journal of Immunology
  - Journal of Infectious Diseases
  - Journal of Laboratory and Clinical Medicine
  - Journal of Leukocyte Biology
  - Journal of Lipid Research

Journal of Thrombosis and Thrombolysis  
 Journal of Virology  
 Laboratory and Clinical Investigation  
 Life Sciences  
 Nature Medicine  
 Nutrition Research  
 1993 Review Board Member, Immunology and Infectious Diseases  
 2004-Present Reviewing Editor, Alcoholism: Clinical and Experimental Research  
 2005-Present Managing Editor, Frontiers in Bioscience (invited)  
 2006-2011 Associate Editor, Hepatology  
 2007-Present Editorial Board Member, World Journal of Gastroenterology  
 Editorial Board, Substance Abuse Research and Treatment  
 2008-Present Editorial Advisory Board Member, Alcohol Research and Health  
 2008-Present Editorial Board, International Journal of Interferon, Cytokine & Mediator Research  
 2009-2013 Editor, Liver Disease Review Letters

### **Scientific Review Groups (NIH):**

#### Chair (Ad hoc)

2000 Chair, Special Emphasis Panel; Lung Biology and Pathology Study Section, CSA, NIH  
 2008-2009 Chair, ZAA1 BB (02) Study Section

#### Permanent Member

1994-1995 Appointed Member, NIH Study Section: Immunology and AIDS Subcommittee, Alcohol Biomedical Research Review Committee Member (study section terminated due to DRG restructuring)  
 2005-2009 Member, Hepatobiliary Pathophysiology Study Section (HBPP)

#### Ad Hoc Member

1992 Site visit team member, General Clinical Research Center Committee, NIH  
 1993 Site visit team member, Alcohol Center Grants Review Committee, NIAAA  
 1994 Alcohol Center Grants Final Review Committee, NIAAA/NIH  
 1995 Member of Special Review Committee, NIAAA/NIH  
 1996 Member of Special Review Committee, NIAAA/NIH  
 1996 Member of Special Review Committee, NIAAA/NIH  
 1996-1998 AIDS and Related Research, IRG, NIH  
 1993-1996 Special Emphasis Panels, NIAAA  
 1999-2000 ALTOX-4 IRG, NIAAA, NIH  
 2000 Special Emphasis Panel; Lung Biology and Pathology Study Section, CSA, NIH  
 2001 NIAAA Special Emphasis Panel/NIH  
 2001 NIAAA AA-1 Study Section/NIH  
 2002 ZAA1 AA, NIAAA  
 2003 NIH AIDS Special Emphasis Panel  
 2003 ZRG-1 GMA-3 Study Section  
 ZRG-1 GMA-2 Study Section  
 ZRG-1 ALTOX-4 Study Section  
 2004 XNDA Study Section  
 HBPP Study Section  
 IHD Study Section  
 2005 HBPP  
 ZRG1 DIG-B  
 ZAT1 G (NCAM)  
 2006 Alcohol Research Centers SRC, Member, NIAAA  
 2006 Alcohol Research Centers, NIAAA  
 2009 Chair, ZAA1 BB (02) Study Section

#### Grant Reviews (Local)

1998, 2005 Diabetes Endocrinology Research Core, University of Massachusetts Medical Center, Worcester, MA  
 2007-Present University of Massachusetts Institutional Pilot Grants  
 2008-Present UMMS, Clinical Translational Research Pilot Grants

Grant Reviews (National)

1992 Ad hoc reviewer, Louisiana Board of Regents Scientific Grants  
 1993 Ad hoc reviewer, Howard University, Washington, DC  
 1994 Ad hoc reviewer, Nations Bank Trust  
 1994 Ad hoc reviewer, Department of Veterans Administration  
 2000 Ad hoc reviewer, Loyola University, Maywood, IL  
 2004 Reviewer, AASLD Research Awards  
 2007 Reviewer, AASLD Research Awards  
 2008 Reviewer, AASLD Research Awards  
 2009 Ad hoc reviewer, University of Cincinnati Research Awards

Grant Reviews (International)

2004 European Research Advisory Board  
 2009 Wellcome Trust, United Kingdom

**Committee Assignments:**National

1993 Organizer, Second Annual Alcohol and Immunology Research Interest Group Meeting  
 1997 Symposium Organizer and Chair, Joint Meeting of the Research Society on Alcoholism and the International Society of Biomedical Research on Alcoholism  
 1998 Chair, Alcohol and Inflammation Workshop, NIH, Bethesda, MD  
 2001 Chair and Organizer, Research Society on Alcoholism Satellite: New Aspects of Immunomodulation by Alcohol  
 2001-2003 Appointed Member, Basic Research Committee, AASLD  
 2001-2003 Abstract Reviewer for the Hepatotoxicity and Cell Death Group, AASLD  
 2004 Organizer, Satellite Session of the Annual RSA Meeting: Mechanisms of Alcohol-Mediated Organ and Tissue Damage: Inflammation and Immunity, Vancouver, Canada  
 2004-2005 Organizer, AASLD Single Topic Conference 2005: What's New in Hepatitis C, Chicago, IL  
 2004 Committee Member, Trans-NIH Action for Liver Disease Research  
 2002-Present Abstract Reviewer, AASLD  
 2006 Nominating Committee, AASLD  
 2006-2008 Chair, Basic Research Committee, AASLD  
 2006-2008 Education Oversight Committee, AASLD  
 2006 Course Director, AASLD Basic Research Workshop: Toll-like receptors in liver disease  
 2006 Course Director, AASLD/NIH Corner: NIDA/AASLD Workshop  
 2007 Appointed Member, National Commission for Digestive Diseases  
 2008-2011 Organizer, Satellite Meeting of the Research Society on Alcoholism (annually)  
 2009-2011 Chair, NIH Liaison Committee, AASLD  
 2009 Organizer and Course Director, AASLD Basic Research Single Topic Conference  
 2009 Organizer, NIH Corner, AASLD Annual meeting

University of Massachusetts Medical School

1992-1994 Research Committee, Department of Surgery  
 1992-1995 Animal Facilities Advisory Committee  
 1993-1996 Committee for the Protection of Human Subjects in Research  
 1996-2000 Institutional Animal Care and Use Committee  
 1999-Present Scientific Council, University of Massachusetts Medical School  
 2001-Present Millennium MD/PhD Program, Advisory Board Member, UMass Med School  
 2002-2004 Cancer Risk Behavior Program, Program Leader, UMass Cancer Center  
 2003-Present Clinical Trials Unit Advisory Committee  
 2004-Present Promotions Committee, Department of Medicine  
 2009 Search Committee

Graduate School of Biomedical Sciences, University of Massachusetts

1990- Immunology/Virology Graduate Program Committee  
 1992-2000 Qualifying Exam Committee, Immunology/Virology Program  
 1994-1996 Course Coordinator, Clinical Immunology, Immunology/Virology Program  
 1995 Thesis Committee, Immunology/Virology Program  
 1996 Minority Summer Fellowship Program Committee  
 2000 Qualifying Exam Committee, Neuropharmacology Program

2003 Qualifying Exam Committee, Neuropharmacology Program  
 2003-2004 Rotation Mentor (Student, S. Chang), Immunology/Virology Program  
 2004-2008 Thesis Advisor (Student, S. Chang) Immunology/Virology Program  
 2005-Present Qualifying Exam Committee, Immunology/Virology Program  
 2006-2009 Thesis Advisor (MD/PhD Student, B. Nath)

#### UMass Memorial Health Care

1995-2000 Rheumatology Training Program, UMass Memorial Medical Center  
 1999-2002 Trauma Training Program, UMass Memorial Medical Center  
 2000-2001 Liver Transplant Conference Planning Committee, UMass Memorial Medical Center, Worcester, MA  
 2003-2009 Bloodborne Pathogen Advisory Committee, UMass Memorial Medical Center, Worcester, MA

#### **Professional Societies:**

1983-Present Hungarian Society of Immunology  
 1984-Present Hungarian Society of Chemotherapy  
 1984-Present Hungarian Society of Allergy and Clinical Immunology  
 1990-Present Society for Leukocyte Biology (SLB)  
 1990-Present Research Society on Alcoholism (RSA)  
 1991-Present International Society for Biomedical Research on Alcoholism  
 1991-Present American Association of Immunologists (AAI)  
 1994-Present American College of Physicians  
 1998-Present American Association for Study of Liver Disease (AASLD)  
 1998-Present American Gastroenterological Association (AGA)  
 2000-Present Clinical Immunology Society  
 2000-Present International Endotoxin Society  
 2001-Present International Cytokine Society  
 2001-Present AASLD, Abstract Review Committee  
 2001-2009 AASLD, Chair, Basic Research Committee (2006-2009)  
 2004-Present Hungarian Gastroenterology Society (Honorary member)  
 2007-Present European Society on Studies of Liver Disease (EASL)  
 2009-Present American Society of Gastrointestinal Endoscopy (ASGE)  
 2009-Present AASLD, Chair, NIH Liaison Committee  
 2009-2013 Member, National Advisory Council on Alcohol Abuse and Alcoholism

#### **INVITED TALKS AND VISITING PROFESSORSHIPS**

##### **Invited Lecturer / Plenary Presentation:**

1991 Invited Lecturer, Immunology Seminar Series, University of South Florida, Tampa, FL  
 1991 Invited Speaker, Immunomodulators: Preclinical and Clinical Evaluation, Capri, Italy  
 1992 Invited Speaker, 2<sup>nd</sup> Symposium on Alcohol and Immunology, Eger, Hungary  
 1992 Invited Lecturer, 2<sup>nd</sup> International Congress on Alcohol, Drugs of Abuse, and Immunomodulation, Tucson, AZ  
 1993 Invited Speaker, 3<sup>rd</sup> Symposium on Alcohol and Immunology, Vail, CO  
 1994 Invited Speaker, Immunocompromised Surgical Patient Symposium, Snowbird, UT  
 1994 Invited Lecturer, 3rd International Congress - Trauma, Shock, Sepsis, Munich, Germany  
 1994 Invited Speaker, Research Society of Alcoholism, Annual Conference, 1994, Maui, Hawaii  
 1995 Invited Speaker, Research Society of Alcoholism, Annual Conference, Steamboat Springs, CO  
 1996 Invited Speaker, Alcohol-Immunology Research Interest Group, Washington, D.C.  
 1996 Invited Speaker, Research Society on Alcoholism and ISBRA Joint Conference, Washington, D.C.  
 1997 Invited Lecturer, Behavioral Immunology Study Group, Deaconess Hospital, Boston, MA  
 1997 Invited Lecturer, Immunology Section, Beth-Israel Hospital, Boston, MA  
 1997 Invited Speaker, Immunology Seminars, National Cancer Institute, Frederick, MD  
 1997 Invited Lecturer, Alcohol: Implications on Health and Disease, University of Nebraska, Omaha, NE  
 1997 Invited Speaker, Symposium on Alcohol Induced Immunopathology, New Orleans, LA  
 1998 Invited Lecturer, Digestive Disease Week, New Orleans, LA

- 1998 Invited Lecturer, Alcohol Research Center, Louisiana University Medical School, New Orleans, LA
- 1998 Invited Speaker, Alcohol-Immunology Research Interest Group, Hilton Head Island, SC
- 1998 Invited Speaker, Ethanol and Intracellular Signaling: from Molecule to Behavior, Satellite Meeting to International Society for Biomedical Research on Alcoholism, Lund, Sweden
- 1999 Invited Lecturer, Trauma Research Institute, Loyola Univ. Med. School, Maywood, IL
- 1999 Invited Speaker, Workshop on Alcohol and Immunology/AIDS, NIH, Bethesda, MD
- 2000 Invited Lecturer, Pathophysiology Seminar Series, Brown University, Providence, RI
- 2000 Invited Lecturer, Department of Medicine, University of Iowa, Iowa City
- 2000 Invited Speaker, Society of Toxicology, Annual Meeting, Philadelphia, PA
- 2000 Invited Speaker, Research Society on Alcoholism, Denver, CO
- 2000 Invited Speaker, Hungarian National Academy of Sciences and Immunology Society, Budapest, Hungary
- 2001 Invited Speaker, Department of Medicine, University of North Carolina, Chapel Hill, NC
- 2001 Invited Speaker, Research Society on Alcoholism Symposium 2001, Montreal, Canada
- 2002 Selected presentations (2), Digestive Disease Week, San Francisco, CA.
- 2002 Invited Speaker, European Macrophage and Dendritic Cell Society, Basel, Switzerland
- 2003 Plenary Presentation, DDW, Orlando, FL
- 2003 Selected oral presentation, AAI, Denver, CO
- 2003 Selected oral presentation, Annual Meeting of the Society for Leukocyte Biology, Philadelphia, PA
- 2003 Selected oral presentation, AASLD, Boston, MA
- 2003 Invited Speaker, Alcohol-Immunology Research Group, Maywood, IL
- 2004 Visiting Professor, Harvard Medical School, Beth Israel Deaconess Hospital, Boston, MA
- 2004 Invited Speaker, AASLD Single Topic Conference: HCV Immunopathogenesis
- 2004 State-of-the-Art Lecture, 46<sup>th</sup> Annual Meeting of the Hungarian Society of Gastroenterology, Balatonaliga, Hungary
- 2004 Selected oral presentations (2), Digestive Disease Week, New Orleans, LA
- 2004 Invited Speaker, Mechanisms of Alcohol-Mediated Organ and Tissue Damage: Inflammation and Immunity Satellite meeting to RSA, Vancouver, CA
- 2004 Invited Speaker, ISBRA Satellite Meeting on Alcohol and the Liver, Bordeaux, France
- 2004 Invited Speaker, European Macrophage and Dendritic Cell Society Annual Meeting, Barcelona, Spain
- 2004 Visiting Professor, University of Nebraska Medical Center, Omaha, Nebraska
- 2004 Visiting Professor, Case Western Reserve University, Cleveland, Ohio
- 2005 Invited Speaker, Semmelweis University Medical School, Budapest, Hungary
- 2005 Invited Speaker, 7<sup>th</sup> Conference in Anesthesiology and Intensive Care, Berlin, Germany
- 2005 Invited Presentation, Hepatitis 2005, Varadero, Cuba (declined due to travel restrictions)
- 2005 Invited Speaker, HCV Symposium, Rockefeller and Cornell Universities, New York NY
- 2005 Invited Speaker, University of Texas Southwestern, Galveston, TX
- 2005 Invited Speaker, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
- 2005 Invited Speaker, Research Society on Alcoholism, Santa Barbara, CA
- 2005 Selected Oral Presentations (2) Digestive Disease Week, Chicago, IL
- 2005 Selected oral presentation, AAASLD, San Francisco, CA
- 2006 Invited Speaker, Massachusetts General Hospital, Harvard Med. School, Boston, MA
- 2005 Session Chair and Presenter, NIAAA/AASLD Corner, San Francisco, CA
- 2006 Session Chair, 2 oral presentations, AAI Annual Meeting, Boston, MA
- 2006 Session Chair, 2 oral presentations, DDW 2006
- 2006 Invited Speaker, Symposium on Moderate Alcohol Consumption: Health Risks and Benefits, Cambridge, MA, May 2006
- 2006 Invited Speaker, UCSF Liver Conference, Sonoma, CA, May 2006
- 2006 Invited Speaker, The First Tampere Consensus Workshop on Pancreatitis, Tampere, Finland
- 2006 Selected Oral Presentation, 13<sup>th</sup> International HCV conference, Cairns, Australia.
- 2006 Alcohol, Intestinal Bacterial Growth, Intestinal Permeability to Endotoxin and Medical Consequences, NIAAA, October 2006
- 2006 AASLD Research Workshop, Organizer and Invited Speaker, October 2006

- 2006 Gastroenterology Research Seminar Series, Beth Israel Deaconess Medical Center, Boston, MA, December 2006
- 2007 Gastroenterology Research Seminar, Vanderbilt University, Nashville TN, March 2007
- 2007 Hepatitis Single Topic Conference: Interferon & Ribavirin in Hepatitis C Virus Infection: Mechanisms of Response and Non-Response, March Chicago, IL
- 2007 GI Research Seminar, Albert Einstein University, March Bronx, NY
- 2007 Gastroenterology Research Seminar, University of Pennsylvania, Pittsburg, PA, April
- 2007 Pathology Seminar, Dartmouth Medical School, May Hanover NH
- 2007 Selected Oral Presentations, 2007 Digestive Disease Week, May Washington, DC
- 2007 Invited Speaker, Alcohol-Trauma Symposium, Shock Society Annual Meeting, June Baltimore, MD
- 2007 Invited Speaker, Research Society on Alcoholism, Chicago, IL
- 2007 Organizer, Speaker RSA Satellite Symposium, Chicago, IL
- 2007 Invited Speaker, Indian National Association for Studies in Liver, New Delhi, India
- 2007 Invited Speaker, All India Institute of Medical Science, New Delhi, India
- 2007 Early Morning Workshop, Faculty, AASLD, Boston, MA
- 2007 Selected Oral Presentation, Society for Leukocyte Biology, Boston, MA
- 2007 Selected Oral Presentation, International Hepatitis Meeting, Glasgow, Scotland
- 2008 Invited Speaker, AASLD Single Topic Conference on Hepatitis C, Chicago, IL
- 2008 Invited Speaker, University of Rochester, NY
- 2008 Dean's Special Lecture, Georgetown University, Washington, DC
- 2008 Invited Speaker, University of Pittsburgh, Pittsburgh, PA
- 2008 Invited Speaker, Immunology/Pathobiology Graduate Program, University of Washington, Seattle, WA
- 2008 Medical Grand Rounds, Northwestern University, Chicago, IL
- 2008 Invited Plenary Speaker, European Association for the Studies of Liver Diseases (EASL), May, Milan, Italy
- 2008 DDW, Selected Oral Presentations, May, San Diego, CA
- 2008 Early Morning Workshop, Faculty, DDW, San Diego, CA
- 2008 Invited Speaker, Innate Immunity Conference, Chania, Greece
- 2008 Organizer, Speaker RSA 2008 Satellite Symposium, Washington, DC, June
- 2008 Postgraduate Course Faculty and Speaker, RSA 2008, Washington, DC, June
- 2008 Postgraduate Course Faculty, RSA, Washington, DC, June
- 2008 Grant Writing Workshop Faculty, RSA, Washington, DC
- 2008 Invited Speaker, Falk Gastro-Conference, September, Mainz, Germany
- 2008 Invited Speaker, 15<sup>th</sup> International Symposium on Hepatitis C Virus & Related Viruses, San Antonio, TX
- 2008 Invited Speaker, 59<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, November
- 2008 Early Morning Workshop, Faculty, AASLD, San Francisco, CA
- 2008 Invited Speaker, Louisiana State University Health Sciences Center – Shreveport, LA
- 2008 Invited Speaker, Molecular Gastroenterology Symposium, Academy of Sciences, Budapest Hungary
- 2008 Keynote Speaker, Annual Meeting, Hungarian Internal Medicine Society, Budapest, Hungary
- 2008 Invited Speaker, Transplant Institute, Prague, Czech Republic
- 2009 Visiting Professor, Yale University School of Medicine
- 2009 Visiting Professor, Department of Surgery, Cincinnati School of Medicine
- 2009 Keynote speaker, 1st Symposium on Liver Immunology and Immune Therapy for Viral Hepatitis, Beijing, China
- 2009 Visiting Professor, Beijing Institute of Infectious Diseases, Beijing, China
- 2009 Invited Speaker, Immunology Program, Centre de Recherché de l'Hotel-Dieu de Quebec, Quebec City, Canada
- 2009 Invited Faculty and Speaker, AGA Career Development Workshop, Phoenix, AZ
- 2009 Visiting Professor, Liver Center, Keck School of Medicine, Los Angeles, CA
- 2009 State-of-the-Art Lecture, DDW
- 2009 Special Lecturer, 4<sup>th</sup> Symposium on ALPD and Cirrhosis, Hurghada, Egypt
- 2009 Visiting Professor, Division of Biology and Medicine, Brown University, Providence, RI



|      |  |
|------|--|
| 2009 | Early Morning Workshop Faculty, AASLD, Boston, MA  |
| 2009 | Organizer and Speaker, NIH Corner, AASLD, Boston, MA   |
| 2009 | Visiting Professor Mayo Clinic, Rochester, MN  |
| 2010 | Invited speaker, Rockefeller University, Center for the Study of Hepatitis C Seminar Series, New York, NY                            |
| 2010 | Invited speaker, University of Houston, Department of Pharmacological and Pharmaceutical Sciences, Houston, TX                       |
| 2010 | Invited speaker, Academic Skills Workshop and MD/PhD Program, Academic Skills Workshop, Houston, TX                                  |
| 2010 | Invited speaker, The 20 <sup>th</sup> Conference of the Asian Pacific Association for the Study of the Liver (APASL), Beijing, China |
| 2010 | Invited speaker, National Transplantation and Immunology Meeting, Institute of Immunology, Shanghai, China                           |

### Community Activities:

|              |  |
|--------------|--|
| 2002-Present | American Liver Foundation, Advisory Board Member, New England Chapter            |
| 2008         | Invited Speaker, Hungarian Medical Association of America, Massachusetts Chapter |

## RESEARCH, TEACHING AND CLINICAL CONTRIBUTIONS

### Research Funding Information:

#### 1) Basic Science Funding

|           |   |  |
|-----------|---|--|
| 1989-1994 | NIH RO1 GM Analysis of Immune Status of Trauma and Surgical Patients                      | Co-PI<br>PI: C. Miller                   |
| 1990-1995 | NIH R29 AA Ethanol's Role in Mediation of Monocyte Immunosuppression                      | PI                                       |
| 1991      | NIH/ADAMHA Small Instrumentation Program  | PI                                       |
| 1992      | American Liver Foundation, Student Research Fellowship (Student: Maria Puppolo)           | Sponsor                                  |
| 1992-1993 | NIH/NIAAA Minority Supplement (Student: Ann Isaac)  | PI                                       |
| 1993-1995 | NIH R03-AA09076 Ethanol Induced Alteration of Monokine Production                         | PI                                       |
| 1994-1996 | NIH/NIDA Position for a post-doctoral fellow supported by Immunology Training Grant       |  |
| 1995-2004 | NIH RO1 AA08577 Ethanol's Role in Mediation of Monocyte Immunosuppression                 | PI                                       |
| 1998-2008 | NIH R01 AA11576 Alcohol and Monocyte Signaling  | PI                                       |
| 1999-2007 | NIH/NIDDK HALT-C Trial  | PI, since 2005                           |
| 1998-2003 | Rheumatology Training Grant   | Faculty Member<br>PI: R Zurier           |
| 1998-2006 | Immunology Training Grant   | Faculty Member<br>PI: R. Welsh           |
| 1999-2002 | Trauma Training Grant   | Co-Investigator<br>PI: C Miller-Graziano |
| 2000-2003 | NIH R21AA/DK12862 Hepatitis C, alcohol and dendritic cells                                | PI                                       |
| 2003-2008 | NIH R01 AA14372 HCV, alcohol, host defense  | PI                                       |
| 2004-2006 | NIH R13 Mechanisms of Alcohol-Mediated Organ and Tissue Damage: Inflammation and Immunity | PI                                       |
| 2004-2007 | NIH R21 AA14238 Heat shock and alcohol induced liver injury                               | Co-PI<br>PI: P Mandrekar                 |

|           |  |                                    |
|-----------|--|------------------------------------|
| 2004-2005 | AASLD Nurse Practitioner Fellowship Grant (Donna D'Agostino)   | Co-Mentor                          |
| 2007-2009 | 1 R21AA01657-01A1 Alcohol disrupts TLR4 signaling in lipid rafts                                       | Co-Investigator<br>PI: A Dolganiuc |
| 2004-2010 | NIH 5R01 AA008577-18 Ethanol's Role in Mediation of Monocyte Immunosuppression                         | PI                                 |
| 2007-2011 | NIH 1 F30 AA017030-01 HIF Dependent Pathways and Acetylation Events In Alcohol Mediated Liver Injury   | Mentor<br>PI: B. Nath              |
| 2008-2012 | NIH 5R01DK075635-02 Toll Like Receptor – Mediated Pathways in Liver Injury                             | PI                                 |
| 2008-2011 | NIH 5 R13 AA017357-02 Mechanisms of Alcohol Mediated Organ and Tissue Damage                           | PI                                 |
| 2008-2013 | NIH 5 R01 AA011576-11 Alcohol and Monocyte Signaling   | PI                                 |
| 2008-2013 | NIH 5 R37AA014372-07 HCV, Alcohol and Host Defense   | Principal Investigator             |
| 2009-2011 | NIH 1 R21 AA017544-01A2 Hypoxia-inducible Factors in Alcoholic Liver Disease                           | PI                                 |
| 2005-2010 | NIH/NIDDK NO1-DK-9-2326 The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (Halt-C) Trial | Local site PI                      |
| 2009-2011 | NIH/NIAAA 1R01AA017729-01A1 TLR4 Signaling in Alcoholic Liver Disease                                  | PI                                 |
| 2009      | NIH 1R01AA017212-01A1 Acute Alcohol and Calcium-dependent LPS-triggered Activation of Macrophages      | CI                                 |

## 2) Clinical/Translational Research Funding

### a) Principal Investigator:

| Year         | Trial  | Sponsor                       |
|--------------|--|-------------------------------|
| 2002-Ongoing | A randomized placebo controlled trial of Rosiglitazone in NASH   | Glaxo-Smith Kline             |
| 2005         | A phase IIB study is an open label study to evaluate the safety and viral activity of NM283 with Peg-Interferon Alfa-2a in naïve patients  | IDENIX NV-08a-006             |
| 2005         | The Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) Trial: A randomized controlled trial to evaluate the safety and efficacy of long-term Peginterferon alfa-2a for treatment of chronic hepatitis C in patients who failed to respond to previous interferon therapy | National Institutes of Health |
| 2005         | PO3471 Comparison of PEG-Intron 1 □g/kg/wk Plus REBETOL vs. PEGASYS 180□□ g/wk Plus COPEGUS in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1   | Schering-Plough               |
| 2006         | A multicenter longitudinal study of drug and complementary and alternative medication (CAM)-induced liver injury   | NIH                           |
| 2006         | Idiosyncratic liver injury associated with drugs (ILIAD): A retrospective study  | NIH                           |
| 2006         | A Phase 1 study that studies non-responder, relapser or treatment naïve Hepatitis C subjects.  | Novartis                      |
| 2006-Ongoing | Prove 1. VX-950 VX05-950-104. A Phase 2 study of VX-950 in combination with Peginterferon Alfa-2a (Pegasys)with and without ribavirin (Copegus) in subjects with hepatitis C.  | Vertex                        |
| 2006-Ongoing | HCV-796. A Phase 2, randomized, open-label study of the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with Peginterferon alfa-2b (PEG-Intron) plus Ribavirin (REBETROL) versus PEG-Intron plus REBETOL in subjects with Hepatitis C Virus        | Wyeth                         |

|              |   |                      |
|--------------|---|----------------------|
|              | genotype 1 infection  |                      |
| 2007         | NASH. A pilot study of Rosiglitazone treatment in patients with non-alcoholic steatohepatitis.  | GlaxoSmith Kline     |
| 2007         | PNalt Ext Study.  | Roche                |
| 2007         | NM283 (004). A randomized, Phase IIb clinical trial to evaluate the safety and antiviral activity of NM283 and the combination of pegylated Inteferon plus NM283, in patients with chronic Hepatitis C who have previously failed to respond to standard therapy.   | Idenix               |
| 2007         | NM283 (006). A Phase IIb, clinical trial to evaluate the combination of pegylated Interferon Alfa plus Valopicitabine (MN283) in treatment-naïve patients with chronic Hepatitis C.   | Idenix               |
| 2007         | FBX104114. Antifibrosis. A double-blinded, randomized, placebo-controlled multi-center, Phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic Hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy.   | GlaxoSmith Kline     |
| 2007         | Prove 1. VX-950 VX05-950-104. A phase 2 study of VX-950 in combination with Peginterferon Alfa-2a (Pegasys®), with and without ribavirin (Copegus®) in subjects with Hepatitis C Vertex 2006S.  | Vertex               |
| 2006-2010    | NIM811B. A randomized, double-blind, placebo controlled, multi-center, time-lagged parallel, multiple-dose, escalating-dose study to assess safety tolerability, pharmacokinetic and pharmacodynamic profiles following administration of NIM811 in patients with viral Hepatitis C genotype 1 (HCV-1).   | Novartis             |
| 2007         | Paradigm. A randomized, multicenter, double-blinded, Phase IV study comparing the safety and efficacy of Pegasys® 180 □g plus Copegus® 1000/1200 mg to the currently approved combination of Pegasys® 180 □g plus Copegus® 800 mg in Interferon-naïve patients with chronic Hepatitis C genotype 1 virus infection co infected with human immunodeficiency virus (HIV-1). | Roche                |
| 2007-2010    | Entecavir. A study to describe the antiviral effect of entecavir (ETV) in Blacks/African Americans and Hispanics with chronic HBV infection who are Nucleoside/tide-Naïve.  | Bristol Myers Squibb |
| 2007-2010    | TPL108390. Eltrombopag ENABLE 1. A randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with HCV infection who are otherwise eligible to initiate antiviral therapy.  | GlaxoSmith Kline     |
| 2008-Ongoing | TPL109390. ENABLE 2. A randomized, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with HCV infection who are otherwise eligible to initiate antiviral therapy.  | GlaxoSmith Kline     |
| 2008-Ongoing | Vertex Rollover Study. Telaprevir (VX06-950-107). A Phase 2 rollover protocol of Telaprevir (VX-950) in combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in subjects who did not achieve or maintain an undetectable HCV RNA level through sustained viral response (SVR).  | Vertex               |
| 2008-Ongoing | Vertex Advanced (108) VX07-950-108. A Phase 3 study of 2 dose regimens of tellaprevir in combination with   | Vertex               |

|                        |   |                         |
|------------------------|---|-------------------------|
|                        | Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus) in treatment naïve subjects with Genotype I chronic Hepatitis C.  |                         |
| 2008-Ongoing           | Vertex 111 ILLUMINATE (VX08-950-111). A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®).                                      | Vertex                  |
| 2008-Ongoing           | Vertex Tibotech C216 REALIZE (VX-950-TiDP24). A randomized, double-blind, placebo-controlled Phase III trial of telaprevir with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) in subjects with Genotype I chronic Hepatitis C infection who did not achieve sustained virologic response following prior treatment with pegylated interferon plus ribavirin. | Vertex                  |
| 2009-Ongoing           | Conatus Pharmaceuticals (CTS-1027-03). A Trial of CTS-1027 in interferon- Naïve Hepatitis C patients.   | Conatus Pharmaceuticals |
| IRB Approval Pending   | Novelos Therapeutics (NOV-205-C201). A phase 2 trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) who have failed treatment with Pegylated Interferon plus Ribavirin.  | Novelos Therapeutics    |
| IRB Approval Pending   | Bristol Myers Squibb (Protocol AI447016). A Phase 2a/2b study of BMS-650032 in combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve subject with Genotypes 1 and 4 Chronic Hepatitis C Infection.  | Bristol Myers Squibb    |
| IRB Submission Pending | MassBiologics (Protocol MBL-HCV1-10-02). A Phase II Randomized, Double-Blind, Placebo Controlled study of the Clinical Effectiveness of a Human Monoclonal Antibody against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) in Hepatitis C Infected Patients Undergoing Liver Transplantation.   | MassBiologics           |
| IRB Submission Pending | Vertex Tibotec BVBA (VX-950-TiDP24-C219). An open lab, single arm, roll over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C216 trial who failed therapy for virologic reasons.   | Vertex                  |

## b) Co-Investigator:

| Year | Trial   | Sponsor  |
|------|---|----------|
| 2002 | An extension protocol to evaluate the long-term effects of treatment with Peginterferon alfa-2a or Roferon-A for patients with chronic hepatitis C in original studies NV15495, NV 15496, and NV15497                       | Novartis |
| 2004 | An open-label multicenter protocol providing pegylated interferon alfa-wa hepatitis C who have participated in previous protocols   | Roche    |
| 2004 | Phase 2b study of Merimepodib in combinations with Pegylated Interferon alfa-2a and ribavirin in subjects with chronic genotype 1 hepatitis C non-responsive to prior therapy with pegylated interferon alfa and Ribavirin. | Vertex   |

|      |  |                 |
|------|--|-----------------|
| 2004 | Randomized double blind multicenter study to compare the safety and efficacy of Viramidine to Ribavirin in treatment-naïve patients with chronic hepatitis C.  | Valeant         |
| 2006 | A randomized multicenter double-blinded Phase IV study comparing the safety and efficacy of Pegasys 180 $\mu$ g plus Copegus 800 mg in Interferon-naïve patients with chronic hepatitis Genotype 1 virus infection co-infected with human immunodeficiency virus (HIV-1) | Roche           |
| 2006 | Pegylated Interferon alfa-2b and Ribavirin after orthotopic liver transplantation: Efficacy and safety in hepatitis C recurrence therapy   | Schering-Plough |
| 2008 | Ocera AST015. Comparison of different treatment regimens in patients with Stage 1-2 type C Hepatic Encephalopathy: AST-120 vs. Lactulose.  | Ocera           |

### Current Research Activities:

#### Bench Research

1. Immune alterations induced by acute alcohol consumption: My laboratory is one of the few focusing on immunomodulation by moderate alcohol use in humans. In addition to understanding mechanisms for the increased susceptibility to infections after alcohol use, results from our investigations have relevance to decreased cardiovascular morbidity after moderate alcohol use as well as to accelerate liver disease in chronic hepatitis C virus infection. My laboratory studies changes in the interactions between accessory cells (monocytes and dendritic cells) and T lymphocytes after moderate alcohol use. The overall aim of our studies is to delineate the effects of alcohol on antigen presenting cell function and to determine the role of cytokine and co-stimulatory molecules leading to decreased antigen-specific T cell proliferation and impaired antimicrobial defense after alcohol use. This work has been funded by NIH R01 AA08577 since 1989 through 2004.
2. Intracellular signaling pathways in leukocytes mediating altered cytokine production after acute alcohol use: This area of research was initially supported by a small NIH grant R03 for two years, then expanded into an RO1 AA11576 funded from 1998 through 2008. We are studying intracellular signaling mechanisms leading to decreased NF- $\kappa$ B activation in monocyte and immune cells after acute alcohol treatment.
3. Immune mechanisms leading to increased liver injury in HCV plus alcohol: This new exploratory project has been funded by NIH R21 AA12862 from 2000 to 2003 and most recently as an RO1 for an additional 5 years. The hypothesis to be tested is that impaired dendritic cell co-stimulatory activity is a pivotal defect of host response to hepatitis C infection and alcohol further reduces immunity by inhibiting maturation and function of myeloid dendritic cells in HCV. We made the novel observation that HCV core and NS3 proteins are recognized by innate immune cells through the Toll-like receptor 2 and result in intracellular signaling pathways that activate pro-inflammatory cytokine production. Investigation of TLR2-mediated pathways in maintenance of chronic inflammation in HCV infection and liver damage is under investigation.
4. Immunopathogenesis of liver injury in obese mice: This is a developing project in my laboratory to investigate the hypothesis that leptin deficient, ob/ob mice have increased susceptibility to immune-mediated liver injury. We found that in contrast to lean mice, ob/ob mice have an increase in activation of the NF- $\kappa$ B and reduced peroxisome proliferators activator signaling in the liver, and these mechanisms are likely to contribute to increased susceptibility of the fatty liver to liver injury. Recent studies investigate the role of toll-like receptors in liver injury. Results from these experiments have direct clinical relevance to mechanisms of liver injury in non-alcoholic steatohepatitis in humans.

#### Clinical Research

1. Immune mechanisms of increased liver injury in HCV plus alcohol: overlap with bench research project #3.
2. Therapeutic studies in chronic hepatitis C: I am the principal investigator at the UMass Memorial site of the national HALT-C trial supported by NIH.

3. Therapeutic approaches in non-alcoholic steatohepatitis (NASH). NASH has recently been recognized as one of the most prevalent liver diseases in the USA, and the most common cause of cryptogenic cirrhosis. I am the PI on an investigator initiated clinical trial of Rosiglitazone in NASH.
4. Fatty liver disease in morbidly obese patients undergoing bariatric surgery. This newly initiated project under my leadership is a collaboration with the bariatric surgery group at UMass to investigate the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in the bariatric surgery patient population and to investigate the effect of surgery on the natural history of NAFLD.

## REPORT OF TRAINING AND MENTORING

### Local Contributions:

#### A. Medical School Courses

- 1997-ongoing Pathophysiology of Liver Disease Course, UMMS Lecturer,  
2<sup>nd</sup> year medical students 6 hours contact time, 10 hours preparation time (annually)
- 2000- Management of GI Diseases Course, UMMS  
Lecturer, 3<sup>rd</sup> year medical students  
6 hours contact time, 6 hours preparation time (annually)
- 1997-1998 GI Rotation for Medical Students, UMMS  
Instructor, Gastrointestinal Diseases-Hepatology  
3<sup>rd</sup> and 4<sup>th</sup> year medical students/3 months contact time, 20 hours preparation time
- 1997-1998 Physical Diagnosis Course, UMMS and St. Vincent's Hospital  
Physical diagnosis of gastrointestinal and hepatic diseases, Lecturer  
2<sup>nd</sup> and 3<sup>rd</sup> year medical students/6 hours contact time, 4 hours preparation time
- 2007 Director, Clinical/Translational Research Pathway

#### B. Medical Education (See section D. for list of trainees)

- 1997 GI Rotation for Internal Medicine Residents, UMMS  
Instructor, Gastrointestinal Diseases-Hepatology  
Internal Medicine residents/1 month contact time
- 1998 Morning Report  
Clinical case presentation and discussion/1 hour, 3 hours prep. time
- 2000 Endoscopic techniques for surgical residents, UMMS  
Hands-on instruction, 10 hours
- 2001 Medical Student, Resident, Fellow teaching, precepting and mentoring
- 2002 Medical Resident Conference; UMass Memorial Health Care, Viral Hepatitis  
1 hour, 6 hours prep. time
- 2004 Medical Resident Conference, UMass Memorial Health Care, Abnormal LFTs, 1 hour, 6 hours  
prep. time
- 2005 Medical Student Clerkship lecture, Elevated LFTs, Cholestasis/1 hour, 6 hours prep. time
- 2006 Cirrhosis, Variceal Bleed and Hepatic Failure, UMMS, Graduate School of Nursing (annually)
- 2007 GI Bleeding, UMMS, Medical Residency Program
- 2003 GI Bleeding, UMMS, Medical Residency Program

#### C. Local Invited Teaching Presentations

- 1997 Cardiovascular Grand Rounds, UMMS  
Alcohol and cardiovascular disease, Lecturer  
30 cardiology staff and fellows/1 hour contact time, 8 hours prep. time
- 1997 Medical Ground Rounds, St. Vincent's Hospital, Worcester, MA  
Alcoholic Liver Disease, Lecturer  
60 medical staff, residents, students/1.5 hours contact time, 16 hours prep. time
- 1998 Medical Ground Rounds, St. Vincent's Hospital, Worcester, MA  
Hemochromatosis and Wilson's disease, Lecturer  
60 medical staff, residents, students/1.5 hours contact time, 16 hours prep. time

D. Local Invited Research Presentations

- 1996 Cardiovascular Research Center, UMMS  
Inflammatory Monocyte Functions, Seminar speaker: 25 staff, fellows and post-docs/1 hour contact time, 4 hours prep. time
- 1996 Digestive Diseases and Nutrition Research Conference, UMMS  
Alcohol induced immune alterations in vitro, Seminar speaker:  
25 staff, fellows, and post-docs/1 hour contact time, 4 hours prep. time
- 1997 Department of Biochemistry, UMMS  
Ethanol-induced immunomodulation in humans, Seminar speaker  
30 staff, post docs, research personnel/1 hour contact time, 3 hours prep. time
- 1998 Cardiovascular Research Center, UMMS  
Intracellular pathways of alcohol-induced reduction of inflammatory cytokine production,  
Seminar speaker: 25 staff, fellows and post-docs/1 hour contact time, 4 hours prep. time
- 1998 Dept. Medicine Research Conference, UMMS  
Immune-alterations after moderate alcohol use, Seminar speaker:  
100 medical staff, fellows, residents, students/1 hour contact time, 6 hours prep. time
- 1999 Digestive Diseases and Nutrition Research Conference, UMMS  
Mechanisms of alcohol induced monocyte dysfunction in human, Seminar speaker  
25 staff, fellows, and post-docs/1 hour contact time, 4 hours prep. time
- 1999 Dept. Medicine Research Conference, UMMS  
Cellular and molecular mechanisms of altered immunity after moderate alcohol use, Seminar  
speaker: 100 medical staff, fellows, residents, students/30 minute contact time, 3 hours prep.  
time.
- 2003 Dept. Medicine Research Conference, UMass Medical School  
Hepatitis C, Alcohol, and Toll-like receptors: The Connection  
100 medical staff, fellows, residents, students/1 hour contact time, 6 hours prep. time
- 2003 Dept. Physiology Research Conference, UMass Medical School  
Regulation of NF $\kappa$ B activation by alcohol in inflammation, Seminar speaker:  
40 faculty, fellows and students/1 hour contact time, 5 hours prep. Time

E. Continuing Medical Education Courses

- 1997-2000 Current topics and case discussions in gastroenterology and hepatology,  
Interdisciplinary GI-Hepatology Conference CME Course, UMMS/12 hours contact time,  
80 hours preparation time
- 1999 New-England AIDS Provider Group, Worcester, MA  
HIV and HCV, Lecturer  
100 staff, nurses, coordinators, fellows, students/90 minute contact time, 16 hours  
preparation time
- 2000 Society for Toxicology, CME Course, Annual Meeting, Philadelphia, PA  
Immunotoxicity of ethanol, Lecturer  
30 minute contact time, 3 hours preparation time
- 2000 Research Society on Alcoholism, CME Course, Annual Meeting, Denver, CO  
Immunological consequences of alcohol use, Lecturer  
30 minute contact time, 3 hours preparation time
- 2000 Liver Transplantation, CME Course, UMass Memorial

- Non-Alcoholic Liver Disease  
30 minute contact time, 5 hours preparation time
- 2001 Liver Transplantation, CME Course, UMass Memorial  
Non-Alcoholic Liver Disease  
30 minute contact time, 5 hours preparation time
- 2001 Trends in Management of GI Disorders UMass Memorial  
Nursing Conference  
45 minute contact time, 5 hours preparation time
- 2002 Primary Care Days, CME Course, UMass Memorial  
Alcoholic and Non-Alcoholic Fatty Liver Disease  
30 minute contact time, 6 hours preparation time
- 2003 UMASS Transplant Conference, CME course  
Non-alcoholic fatty liver disease and liver transplantation  
100 participants, physicians, nurses, coordinators  
30 minutes contact time, 4 hours preparation time
- 2003 Hungarian Medical Association of America, 35<sup>th</sup> Annual Meeting Hepatitis C, CME  
Course, "Pathogenesis of HCV"  
30 minute contact time, 4 hours preparation time
- 2004 AASLD single Topic Conference: Immunovirology of the Liver  
30 minutes contact time, 10 hours preparation time
- 2004 Non-alcoholic Steatohepatitis – State-of-the-Art Lecture  
Hungarian Gastroenterology Society, 5<sup>th</sup> Annual CME Course
- 2005 Clinical aspects and therapy of HCV - State-of-the-Art Lecture  
Hungarian Gastroenterology Society, 5<sup>th</sup> Annual CME Course
- 2005 Medical Grand Rounds, Alcoholic Liver Disease, Berkshire Med. Ctr., Pittsfield, MA
- 2005 Medical Grand Rounds, Non-Alcoholic Liver Disease, Berkshire Med Ctr., Pittsfield, MA
- 2006 Liver Symposium, Alcoholic and Non-Alcoholic Liver Disease, Marlborough, MA
- 2006 AASLD Early Morning Workshop: Innate Immunity in Liver Disease, Annual Meeting,  
Boston, MA
- 2007 DDW/AASLD, Single Topic Conference, Hepatitis, Chicago, IL
- 2007 AASLD Early Morning Workshop: TLRs in the Liver, Annual Meeting, Boston, MA
- 2008 DDW Early Morning Workshop, San Diego, CA
- 2008 RSA, Postgraduate Course: The Immune System and Alcohol, Washington, DC
- 2008 AASLD, Early Morning Workshop, San Francisco, CA
- 2008 Non-alcoholic Fatty Liver Disease, Budapest, Hungary
- 2008 Alcohol-induced Regulation of Inflammation and Immunity, Transplant Symposium,  
Prague, The Czech Republic



2009

GI Grand Rounds, "Clinical implications of recent discoveries in liver immunology".  
Keck School of Medicine, Los Angeles, CA

## **SUPERVISORY RESPONSIBILITIES FOR STUDENTS/FELLOWS**

### **Mentoring of Students**

Undergraduate students enrolled in the Student Enrichment program

| <b>YEARS</b> | <b>DURATION OF PROGRAM</b> | <b>NAME</b>             |
|--------------|----------------------------|-------------------------|
| 1991-1992    | 9 Months                   | Maria Puppolo           |
| 1992-1993    | 24 Months                  | Ann Isaac               |
| 1992-1993    | 9 Months                   | Trista Brown            |
| 1994-1995    | 6 Months                   | Melissa Martinez-Guzman |
| 1995         | 3 Months                   | Kissa Williams          |
| 1997         | 3 Months                   | Amy Tsien               |
| 1998         | 3 Months                   | Nicole Brown            |
| 1999         | 3 Months                   | Jong K. Choi            |
| 1999         | 3 Months                   | Gary Bellerose          |
| 1999-2001    | 15 Months                  | Rabia Nizamani          |
| 2000         | 2 Months                   | John Browne             |
| 2001         | 2.5 Months                 | Lucia Graham            |
| 2001         | 2.5 Months                 | Christopher Marshall    |
| 2001         | 2.5 Months                 | Noemi Baffy             |
| 2002         | 2.5 Months                 | Twan Do                 |
| 2002         | 2.5 Months                 | Erin McKenna            |
| 2002         | 2.5 Months                 | Helder Hernandez        |
| 2003         | 2.5 Months                 | Meghna Mukherjee        |
| 2004         | 2.5 Months                 | Rachel Campbell         |
| 2004         | 2.5 Months                 | Catherine Garcia        |
| 2006         | 2.5 Months                 | Jemmie Chang            |
| 2006         | 2.5 Months                 | Joshlean Fair           |
| 2007         | 2.5 Months                 | Oranmyan Nelson         |
| 2007         | 2.5 Months                 | Christy Webber          |
| 2008         | 2.5 Months                 | Ashley Addea            |
| 2008         | 2.5 Months                 | Briana Gray             |

### Graduate Student Rotations

| <b>YEARS</b> | <b>DURATION OF PROGRAM</b> | <b>NAME</b>     |
|--------------|----------------------------|-----------------|
| 2003         | 3 Months                   | Serena Chang    |
| 2006         | 3 Months                   | Edward Paek     |
| 2006         | 3 Months                   | Alex Lagadinos  |
| 2007         | 3 Months                   | Derek Troubaugh |

### Medical Resident Rotations

| <b>YEARS</b> | <b>DURATION OF PROGRAM</b> | <b>NAME</b>          |
|--------------|----------------------------|----------------------|
| 2005         | 6 months                   | Liam Haveron         |
| 2005-2006    | 3 months                   | Christopher Marshall |
| 2006         | 2 months                   | Taryn Shapiro        |
| 2008         | 1 month                    | Daniel Cho           |
| 2009         | 3 months                   | Michal Ganz          |

### **Graduate Student Thesis Committee Member:**

2003 Audrey Lau, MD/PhD Student, University of Pittsburg, PA

|      |  |
|------|--|
| 2004 | Qun Dai, Louisiana Health Science Center, Shreveport, LA                       |
| 2006 | Kristen Willems, University of Massachusetts Medical School, Worcester, MA     |
| 2006 | Ermelinda Porpiglia, University of Massachusetts Medical School, Worcester, MA |
| 2007 | Prerna Chopra, University of Massachusetts Medical School, Worcester, MA       |
| 2007 | Annie Kruger, University of Massachusetts Medical School, Worcester, MA        |
| 2007 | Edward Paek, University of Massachusetts Medical School, Worcester, MA         |
| 2007 | Richard Robinson, Dartmouth Medical School, Hanover, NH                        |
| 2008 | Patricia Wynne, University of Massachusetts Medical School, Worcester, MA      |
| 2008 | Dipti Karmarkar, University of Massachusetts Medical School, Worcester, MA     |

**Graduate Student Thesis Advisor:**

|           |  |
|-----------|--|
| 2004-2009 | Serena Chang, University of Massachusetts Medical School, Worcester, MA                |
| 2006-2009 | Bharath Nath, MD/PhD Program University of Massachusetts Medical School, Worcester, MA |

**International Medical or Graduate Students:**

| YEARS     | DURATION OF PROGRAM | NAME                               |
|-----------|---------------------|------------------------------------|
| 1999      | 3 Months            | Laszlo Romics                      |
| 2000      | 3 Months            | Attila Markus                      |
| 2001-2003 | 2.5 Years           | Laszlo Romics (PhD thesis advisor) |

**Mentoring Medical Students:**

Jennifer Liu, UMass - Class of 2005

**Mentoring of Postdoctoral Fellows:**

1. Miklos Fogarasi, MD  
Junior postdoctoral fellow, Full time supervision of research, 1990-1991  
Current position: Hematology-oncology Attending, Yale University Med. School
2. Bikash Verma, DVM,  
Postdoctoral fellow, full time supervision of research, 1991-1994  
Current position: Research Program Officer, Harvard School of Public Health
3. Pranoti Mandrekar, Ph.D.  
Senior postdoctoral research associate, full time supervision, 1993-1998  
Current position: Research Associate Professor, University of MA Medical School
4. Linda Newman, Ph.D.  
Junior postdoctoral fellow, full time supervision, 1994-1997  
Current position: Assistant Professor, American University, Springfield, MA
5. Sangeeta Chavan, Ph.D.,  
Postdoctoral fellow, full time supervision, 1997-1998  
Current position: Research fellow, NYU
6. Asok Karuri, Ph.D.  
Senior Postdoctoral Research Associate, full time supervision, 1999-2000
7. Cristina Gavala, M.D.  
Postdoctoral Research Associate, full time supervision, 1999-2000  
Current position: Staff Physician, Department of Medicine, St. Vincent's Hospital, Worcester, MA
8. Yvonne Drechsler, Ph.D.  
Postdoctoral fellow, full time supervision, 1999-2005
9. Angela Dolganiuc, M.D., Ph.D., Postdoctoral Fellow, full time supervision, 2001-2007  
Current position: Research Assistant Professor
10. Laszlo Romics, Jr., M.D, Postdoctoral Fellow, .full time supervision, 2001-2003  
Current position: Staff surgeon, University of Glasgow, Scotland
11. David Johnson, Ph.D., Postdoctoral Fellow, full time supervision, 2002-2003
12. Shilpa Oak, Ph.D., Postdoctoral Fellow, full time supervision, 2002-2004
13. Arumugam Velayudham, M.D., Resident and Clinical Investigator Pathway, Research Mentor 2002-2008.

Current position: Advanced Endoscopy Fellow, University of North Carolina, NC

14. Istvan Hritz, M.D. – Postdoctoral Fellow, full time supervision, 2004-2007  
Current position: General Surgery Fellow
15. Oxana Norkina, M.D. – Postdoctoral fellow, full time supervision, 2005-2007  
Current position: Research Fellow, University of Michigan
16. Adam Leibach, Postdoctoral fellow, full time supervision, 2006-Feb-Oct
17. Doreen Soldato, Postdoctoral Fellow, full time supervision, 2007
18. Shaun Murphy, Postdoctoral Fellow, full time supervision, 2007
19. Shashi Bala, Postdoctoral Fellow, full time supervision, 2008-present
20. Jan Petrasek, Postdoctoral Fellow, full time supervision, 2008-present
21. Timea Csak, Postdoctoral Fellow, full time supervision, 2008-present
22. Maoyin Pang, Postdoctoral Fellow, full time supervision, 2008-present
23. Ivan Levin, Postdoctoral Fellow, full time supervision, 2009-present
24. Wei Hoe, Postdoctoral Fellow, full time supervision, 2009-present
25. Shuye Zhang, Postdoctoral Fellow, full time supervision, 2009-present

#### Mentoring Residents:

|           |                          |
|-----------|--------------------------|
| 1999      | Kinari Worah, M.D.       |
| 2001      | Arum Velayudham, M.D.    |
| 2003-2006 | Gennadyi Bakis, MD       |
| 2004-2007 | Christopher Marshall, MD |
| 2006      | Taryn Shapiro, MD        |
| 2008      | Michal Ganz              |

#### Advisees and Trainees:

| YEARS                  | NAME              | CURRENT POSITION   |
|------------------------|-------------------|--|
| <b>FACULTY ADVISOR</b> |                   |  |
| 1990-1991              | Miklos Forgarasi  | Oncology Fellow, Yale University                                       |
| 1991-1994              | Bikash Verma      | Research Program Officer, HSPH   |
| 1993-1997              | Pranoti Mandrekar | Research Assistant Professor,<br>University of MA Medical School       |
| 1994-1998              | Linda Newman      | Assistant Professor, American<br>University                            |
| 1997-1998              | Sangeeta Chavan   | Research Fellow, NYU   |
| 1999-2000              | Christina Gavala  | Resident, St. Vincent's Hospital,<br>Worcester, MA                     |
| 2001-2003              | Laszlo Romics     | Staff Surgeon, Cork University<br>Hospital, Cork, Ireland              |
| <b>FACULTY MENTOR</b>  |                   |  |
| 2008-2009              | John Chet Ford    | Department of Radiology, University<br>of Massachusetts Medical School |

#### BIBLIOGRAPHY

##### Original Articles:

1. Lukacs K, **Szabo G**, et al. 1984. Stimulating Effect of Tuftsin and its Analogues on the Defective MØ Chemotaxins in Systemic Lupus Erythematosus. *Immunopharmacology*, 7:171-178.
2. Lukacs K, Kawai M, Banyai A, Sonkoly I, **Szabo G**, et al. 1984. Effect of Immune Complexes from SLE Patients on Human MØ Chemotaxis and Fc-receptor Function. *Annals of Rheumatic Diseases*, 43:729-733.
3. Szegedi G, Lukacs KL, Bodolay E, Gulacsi L, Sonkoly I, **Szabo G**, et al. 1985. Inhibiting Effect of MØ-reactive Antibodies on MØ Chemotaxis in Systemic Lupus Erythematosus. *Hematology*, 18(3):175-183.

4. **Szabo G**, Frendl G, et al. Altered granulocyte cytotoxic activity in system lupus erythematosus and mixed connective tissue diseases. *Ann. Immun. Hung.* 1986; 26:657-670.
5. **Szabo G**, Frendl G, et al: 1986. Altered Granulocyte Cytotoxic Activity in Systemic Lupus Erythematosus and Mixed Connective Tissue Disease. *Immunology Hung.*, 26:657-670.
6. Werner E, Bitterlich G, Fuchs D, Hausen A, Reibnegger G, **Szabo G**, et al. 1987. Human Macrophages Degrade Tryptophan upon Induction by Interferon-Gamma. *Life Sciences*, 41:273-280.
7. Bitterlich G, **Szabo G**, et al. 1988. Selective Induction of Mononuclear Phagocytes to Produce Neopterin by Interferons. *Immunobiol.*, 176:228-235.
8. Miller-Graziano C, Fink M, Wu J, **Szabo G**, et al. 1988. Mechanisms of Altered MØ PGE<sub>2</sub> Production in Severely Injured Patients. *Archives of Surgery*, 123:293.
9. Bodolay E, Lukacs K, **Szabo G**, Frendl G. et al. Monocyte functions in patients with mixed connective tissue disease. *Allergol. et Immunopathol.* 1989; 17:(1):39-43.
10. Bodolay E, Lukacs K, Frendl G, **Szabo G**, et al. 1989. Polymorphonuclear Functions in Patients with Mixed Connective Tissue Disease. *Allergol. et Immunopathol.*, 17(4):205-207.
11. Takayama T, Miller-Graziano C, **Szabo G**, et al: 1990. Elevated Tumor Necrosis Factor (TNF) Production Concomitant to Elevated PGE<sub>2</sub> by Trauma Patients' Monocytes (MØ). *Archives of Surgery*, 125:29-35.
12. **Szabo G**, Miller-Graziano CL, Wu JY, et al. 1990. Differential Tumor Necrosis Factor Production by Human Monocyte Subsets. *Journal of Leukocyte Biology*, 47:206-216.
13. **Szabo G**, Miller CL, and Kodys K. 1990. Antigen Presentation by the CD4 Positive Monocyte Subset. *Journal of Leukocyte Biology*, 47:111-120.
14. **Szabo G**, Miller-Graziano CL. 1990. Induction and Regulation of Monocyte Procoagulant Activity. *Transplantation*, 50:301-309.
15. Miller-Graziano CL, **Szabo G**, Kodys K, et al: 1990. Aberrations in Post-Trauma Monocyte (MØ) Subpopulation: Role in Septic Shock Syndrome. *Journal of Trauma*, 30(12):S86-S97.
16. Miller-Graziano CL, **Szabo G**, Griffey K, et al. 1991. Role of Elevated Monocyte TGFβ Production in Post-Trauma Immunosuppression. *Journal of Clinical Immunology*, 11(2):95-102.
17. **Szabo G**, Kodys K, Miller-Graziano CL. 1991. Elevated Monocyte IL-6 Production in Immunosuppressed Trauma Patients. II. Downregulation by IL-4. *Journal of Clinical Immunology*, 11(6) 336-344.
18. **Szabo G**, Kodys K, Miller-Graziano CL. 1991. Elevated Monocyte IL-6 Production in Immunosuppressed Trauma Patients. I. Role of FcRI Crosslinking Stimulation. *Journal of Clinical Immunology* 11(6): 326-335.
19. **Szabo G**, Verma BK, Fogarasi M, Catalano DE. 1992. Induction of Transforming Growth Factor-beta and Prostaglandin E<sub>2</sub> Production by Ethanol in Human Monocytes. *Journal of Leukocyte Biology*, 52:602-610.
20. Verma BK, Fogarasi M, **Szabo G**. 1993. Down-regulation of TNF Activity by Acute Ethanol Treatment in Human Peripheral Blood Monocytes. *Journal of Clinical Immunology*, 13:8-23.

21. **Szabo G**, Verma B, Catalano D. 1993. Selective Inhibition of Antigen-Specific T Lymphocyte Proliferation by Acute Ethanol Exposure: The Role of Impaired Monocyte Antigen Presentation Capacity and Mediator Production. *Journal of Leukocyte Biology*, 54: 534-544.
22. **Szabo G**, Kodys K, Miller-Graziano CL. 1994. Dibutyryl-cAMP Modulation of Receptor Expression and Antigen Presentation Capacity in Monocyte Subpopulations. *International Journal of Immunopharmacology*. 16(2):151-162.
23. **Szabo G**, Puppolo M, Verma B. 1994. Regulatory Potential of Ethanol and Retinoic Acid on Human Monocyte Functions. *Alcoholism: Clinical and Experimental Research*. 18(3):548-554.
24. **Szabo G**, Mandrekar P, Verma B, Isaac A, Catalano D. 1994. Acute Ethanol Consumption Synergizes with Trauma to Increase Monocyte TNF $\alpha$  Production Late Postinjury. *J. Clinical Immunology*. 14(6):340-352.
25. **Szabo G**, Mandrekar P, Catalano D. 1995. Inhibition of Superantigen-induced T cell Proliferation and Monocyte IL-1 $\beta$ , TNF, and IL-6 Production by Acute Ethanol Treatment. *Journal of Leukocyte Biology*. 58:342-350.
26. Mandrekar P, Catalano D, **Szabo G**. 1996. Human Monocyte IL-10 Production is Increased by Acute Ethanol Treatment. *Cytokines* 8:567-577.
27. **Szabo G**, Mandrekar P, Newman L, Catalano D. 1996. Regulation of human monocyte functions by acute ethanol treatment: Decreased TNF, IL-1 and elevated IL-10, TGF $\beta$  production. *Alcoholism: Clin Exp Res*. 20:900-907.
28. **Szabo G**, Girouard L, Mandrekar P, Catalano D. 1996. Acute ethanol treatment augments IL-12 production in activated human monocytes. In: *Interleukin 12: Cellular and Molecular Immunology of an Important Regulatory Cytokine*. *Annals of The New York Academy of Sciences* 795:422-426.
29. Zakhari S, and **Szabo G**. 1996. NF- $\kappa$ B, a prototypical cytokine regulated transcription factor: Implications for alcohol mediated responses. *Alcoholism: Clin Exp Res* 20:236A-242A.
30. **Szabo G**. 1997. Alcohol's contribution to compromised immunity. *Alcohol Health & Research World* 21:30-41.
31. **Szabo G**, Catalano D, Mandrekar P. 1997. Ethanol-induced regulation of NF- $\kappa$ B in monocytes. *Alcoholism: Clin. Exp Res* 21:988-994.
32. Girouard, Mandrekar P, Catalano D, **Szabo G**. 1998. Regulation of monocyte IL-12 production by acute alcohol: A role for inhibition by IL-10. *Alcoholism: Clin. Exp. Res*. 22:211-216.
33. **Szabo G**, Giouard L, Mandrekar P, Catalano D. 1998. Regulation of monocyte IL-12 production: Augmentation by lymphocyte contact and acute ethanol treatment, inhibition by elevated intracellular cAMP. *Int. J. Immunopharmacology* 20:491-503.
34. **Szabo G**. 1998. Monocytes, alcohol use, and altered immunity. *Alcoholism: Clin. Exp Res*, 22: 217s-220s.
35. **Szabo G**, Chavan S, Mandrekar P, Catalano D. 1999. Acute alcohol consumption attenuates IL-8 and MCP-1 induction in response to ex vivo stimulation. *J. Clin. Immunol.* 19:67-76.
36. **Szabo G**. 1999. Consequences of alcohol consumption on host defense. *Alcohol and Alcoholism* 34:830-841.

37. Mandrekar P, Catalano D, **Szabo G**. 1999. Inhibition of LPS-mediated NF- $\kappa$ B activation by ethanol in human monocytes. *Int Immunol*. 11:1781-90.
38. **Szabo G**. 2000. New insights into the molecular mechanisms of alcoholic hepatitis: The role of NF- $\kappa$ B activation? *J. Lab. Clin. Med.* 135:367-369
39. Fang WC, Saltzman J, Rososhandsky S, **Szabo G**, Heard S, Banner B, Katz E. 2000. Acceptance of an ABO-incomplete mismatched liver allograft with the use of Daclizumab and Myaophenolate Mofetil. *Liver Transplantation* 6:497-500
40. **Szabo G**, Katz E, Bonkovsky H. 2000. Management of recurrent hepatitis C after liver transplantation: a concise review. *Am. J. Gastroenterology* 95(9):2164-2170
41. **Szabo G**, Catalano D, Bellerose G, Mandrekar P. 2001. Interferon-alpha and alcohol augment nuclear regulatory factor- $\kappa$ B activation in HepG2 cells and IFN $\alpha$  increases pro-inflammatory cytokine production. *Alcoholism: Clin. & Exp. Res.* 25:1188-1197.
42. **Szabo G**, Gavala C, Mandrekar P: 2001. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. *J. Investigative Medicine*. 49:442-449.
43. **Szabo G**, Mandrekar P, Dolganiuc A, Catalano D, Kodys K. 2001. Reduced alloreactive T cell activation after alcohol intake is due to impaired monocyte accessory cell function and correlates with elevated IL-10 and decreased IFN $\gamma$  levels. *Alcoholism: Clin. & Exp. Res.* 25(12):1766-1772.
44. **Szabo G** & Mandrekar, P. 2002. Ethanol-mediated regulation of transcription factors in immunocompetent cells. *Frontiers in Bioscience* 7, a80-89.
45. Bonkovsky H, Azar R, Bird S, **Szabo G**, Banner B, Thompson M. 2002. Severe Cholestatic Hepatitis Caused by Thiazolidinediones, Risk Associated with Substituting Rosiglitazone for Troglitazone. *Digestive Diseases & Sciences*. 47(7):1632-1637.
46. Drechsler Y, Mandrekar P, Chavan S, **Szabo G**. 2002. FC-gamma receptor crosslinking mediates NF $\kappa$ B activation, reduced antigen presentation capacity and IL-12 production in monocytes without inhibition of myeloid dendritic cell development. *J. Leuk. Biol.* 72:657-667.
47. Mandrekar P, Bellerose G, **Szabo G**. 2002. Inhibition of NF- $\kappa$ B binding correlates with increased nuclear glucocorticoid receptor levels in acute alcohol treated human monocytes. *Alcoholism: Clin. Exp. Res.* 26:1872-1879.
48. Mandrekar P, Dolganiuc A, Bellerose G, Kodys K, Romics L, Nizamani R, **Szabo G**. 2002. Acute alcohol inhibits induction of nuclear regulatory factor  $\kappa$ B activation through CD14/Toll-like receptor 4, interleukin-1, and Tumor necrosis factor receptors: A common mechanism independent of I $\kappa$ B $\alpha$  degradation? *Alcoholism: Clin. Exp. Res.* 26:1609-1614.
49. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Twan D, Romics L, Mandrekar P, Zapp, M, **Szabo, G**. 2003. Hepatitis C virus core and NS3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation *J Immunol*. 170:5615-5624.
50. Dolganiuc A, Kodys K, Kopasz A, Marshall C, **Szabo G**. 2003. Additive inhibition of dendritic cell allostimulatory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction. *Alcoholism: Clin. Exp. Res.* 27:1023-1031.
51. Mandrekar P, Catalano D, Dolganiuc A, Kodys K and **Szabo G**. 2004. Inhibition of myeloid dendritic cell accessory cell function by alcohol correlates with reduced CD80/CD86 expression and decreased IL-12 production. *J. Immunol*. 173(5):3398-3407.

52. Romics, Jr. L, Kodys K, Dolganiuc A, Mandrekar P, **Szabo G**. 2004. Selective priming to Toll-like receptor 4 (TLR4), not TLR2, ligands by *P. acnes* involves up-regulation of MD-2 Hepatology 40:555-564.
53. Romics, Jr. L, Kodys K, Dolganiuc A, Graham L, Velayudham A, Mandrekar P, **Szabo G**. 2004. Diverse regulation of NF- $\kappa$ B and peroxisome proliferator activated-receptors in non-alcoholic fatty liver. Hepatology 40:376-385.
54. Dolganiuc A, Kodys K, Shin S, Finberg R, Golenbock D, Kurt-Jones E, **Szabo G**. 2004 Toll-like receptor 2 mediates inflammatory pathways triggered by hepatitis C virus core and nonstructural 3 proteins Gastroenterology 127(5):1513-1524.
55. **Szabo G**, Catalano D, Mandrekar. 2004. Acute alcohol consumption inhibits accessory cell function of monocytes and dendritic cells. Alcoholism: Clin Exp Res 28:824-828.
56. **Szabo G**, Dolganiuc A, Mandrekar P, White B. 2004. Inhibition of antigen-presenting cell functions by alcohol: implication for hepatitis C virus infection. Alcohol 33:1-9.
57. Romics L. Jr, Mandrekar P, Kodys K, Velayudham A, Drechsler Y, Dolganiuc A, **Szabo G**. 2005. Increased LPS sensitivity in alcoholic fatty livers is independent of leptin deficiency and TLR4 or TLR2 expression. Alcoholism: Clin Exp Res 29:1018-1026.
58. **Szabo G**, Dolganiuc A. 2005. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology 210:237-247.
59. Romics, L. Jr., Dolganiuc A, Kodys K, Mandrekar P, Golenbock D, Jurt-Jones E, **Szabo G**. 2005. Toll-like receptor 2 mediates inflammatory cytokine induction but not sensitization for liver injury by *Propionibacterium acnes*. J. Leukocyte Biology 78:1255-1264.
60. **Szabo G**, Velayudham A, Romics L. Jr., Mandrekar P. 2005. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: The role of Toll-like receptors 2 and 4. Alcoholism: Clin Exp Res 29:140s-145s.
61. Dolganiuc A, Bakis G, Jeliaskova, V, **Szabo G**. 2006. Acute alcohol treatment modulates TLR4 association with lipid rafts Alcoholism: Clin Exp Res 30:76-85.
62. Mandrekar P, Catalano D, White B, **Szabo G**. 2006. Moderate alcohol intake in humans attenuates monocyte inflammatory responses: inhibition of NF- $\kappa$ B and induction of IL-10. Alcoholism: Clin Exp Res 30:135-139.
63. **Szabo G**: 2006. Hepatitis C virus NS5A protein—a master regulator? Gastroenterology 130:995-999.
64. Dolganiuc A, Garcia C, Kodys K, **Szabo G**: 2006. Distinct toll-like receptor expression in monocytes and T cells in chronic HCV infection. World J Gastroenterol 12(8):1198-1204.
65. Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S. 2006. Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity. Alcoholism: Clin. Exp. Res.
66. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, Wheeler M, Zou J. 2006. Cytokines and alcohol. Alcoholism: Clin Exp Res 30:720-730.
67. Oak S, Mandrekar P, **Szabo G**. 2006. TLR2 and TLR4-mediated signals determine attenuation or augmentation of inflammation by acute alcohol in monocytes. J Immunol 176:7628-7635.

68. Drechsler Y, Romics L. Jr., Li W, Kodys K, Mandrekar P, Bach H.F, **Szabo G**. 2006. Heme-oxygenase-1 mediates the anti-inflammatory effects of acute ethanol treatment on IL-10 induction in Monocyte involving p38 MPK activation. *J Immunol* 177:2592-2600.
69. Velayudham A, Hritz, I, Dolganiuc A, Mandrekar, P, Kurt-Jones E, **Szabo G**. 2006. Critical role for Toll-like receptors and the common adaptor, MyD88, in granulomas and sensitization to injury. *J. Hepatology* 45(6):813-824.
70. Spies C, Eggers V, **Szabo G**, Lau A, con Dossow V, Schoenfeld H, Althoff H, Thesis Group D, Schroeder T, Pfeiffer S, Ziemer S, Paschen C, Klein M, Marks C, Miller P, Sander M, Wernecke KD, Achterberg W, Kaisers U, Volk HD: 2006. Intervention of neuroendocrine-immune axis and postoperative pneumonia rate in long-term alcoholics. *Am J Respir. Crit Care Med.* 174(4):408-414.
71. Dolganiuc A, Chang S, Kodys K, Mandrekar P, Bakis G, **Szabo G**. 2006. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. *J Immunol.* 177(10):6758-6768.
72. **Szabo G**, Dolganiuc A, Mandrekar P. 2006. Pattern recognition receptors. *Hepatology* 44:287-298.
73. **Szabo G**, Dolganiuc A. 2006. HCV immunopathogenesis: Virus-induced strategies against host immunity. *Clin Liver Dis* 10(4):753-771.
74. **Szabo G**, Dolganiuc A, Dai Q, Pruett SB. 2007. TLR4, ethanol and lipid rafts: a new mechanism of ethanol action with implications for other receptor-mediated effects. *J Immunol.* 178(3):1243-1249.
75. **Szabo G**. 2007. Moderate drinking, inflammation, and liver disease. *Ann Epidemiol* 17:S49-S54.
76. Chang S, Dolganiuc A, **Szabo G**. 2007. Toll-like receptors (TLR) 1 and 6 are both involved in TLR2-mediated macrophage activation by Hepatitis C Virus core and NS3 proteins. *J Leukoc Biol* 82(3):479-487.
77. **Szabo G**, Mandrekar P, Oak S, Mayerle J. 2007. Effect of ethanol on inflammatory responses. Implications for pancreatitis. *Pancreatology* 7(2-3):115-123.
78. Norkina O, Dolganiuc A, Shapiro T, Kodys K, Mandrekar P, **Szabo G**. 2007. Acute alcohol activates STAT3, AP-1, and SP-1 transcription factors via the family of Src kinases to promote IL-10 production in human monocytes. *J Leukoc Biol* 82(3):752-762.
79. Mandrekar P, Jelizkova V, Catalano D, **Szabo G**. 2007. Acute alcohol exposure exerts anti-inflammatory effects by inhibiting I $\kappa$ B kinase activity and p65 phosphorylation in human monocytes. *J Immunol* 178(12):7686-93.
80. Dolganiuc A, Norkina O, Kodys K, Catalano D, Mandrekar P, Bakis G, Marshall C, **Szabo G**. 2007. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. *Gastroenterology* 133(5):1627-1636.
81. Seef L, Curto T, **Szabo G**, Everson G, Bonkovsky H, Dienstag J, Shiffman M, Lindsay K, Lok A, DiBiscegli A, Lee W, Ghany M. 2008. Herbal product use by persons enrolled in the Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) Trial. *Hepatology* 47(2):605-612.
82. **Szabo G**, Dolganiuc A. 2008. Hepatitis C core protein – The “core” of immune deception? *J Hepatology* 48(1):8-11.
83. Norkina O, Dolganiuc A, Catalano D, Kodys K, Mandrekar P, Syed A, Efros M, **Szabo G**. 2008. Acute alcohol intake induces SOCS 1 and SOCS 3 and inhibits cytokine-induced STAT 1 and STAT 3 signaling in human monocytes. *Alcoholism: Clin Res Exp* 32(9):1565-1573.



84. Hritz I, Velayudham A, Dolganiuc A, Kodys K, Mandrekar P, Kurt-Jones E, **Szabo G**. 2008. Bone marrow-derived immune cells mediate sensitization to liver injury in a MyD88-dependent fashion. *Hepatology* 48(4):1342-1347.
85. Hritz I, Mandrekar P, Velayudham I, Catalano D, Dolganiuc A, Kurt-Jones E, **Szabo G**. 2008. The critical role of Toll-like receptor 4 in alcoholic liver disease is independent of the common TLR adaptor, MyD88. *Hepatology* 48(4):1224-1231.
86. Dolganiuc A, **Szabo G**. 2008. T cells with regulatory activity in Hepatitis C virus infection: what we know and what we don't. *J Leukocyte Biol* 84(3):614-622.
87. Dolganiuc A, Paek E, Kodys K, Thomas J, **Szabo G**. 2008. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. *Gastroenterology* 135(6):2119-2127.
88. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, **Szabo G**. 2009. VSL #3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced NASH model in mice. *Hepatology* 49(3):989-997.
89. Nath B, **Szabo G**. 2009. Alcohol-induced modulation of signaling pathways in liver parenchymal and nonparenchymal cells: Implications for immunity. *Semin Liver Disease* 29(2):166-177.
90. Mandrekar P, Bala S, Kodys K, Catalano D, **Szabo G**. 2009. The opposite effects of acute and chronic alcohol on LPS-induced inflammation are linked to IRAK-M in human monocytes. *J Immunol* 183(2):1320-1327.
91. Dolganiuc A, Petrasek J, Kodys K, Catalano D, Mandrekar P, Velayudham A, **Szabo G**. 2009. MicroRNA expression profile in alcoholic steatohepatitis (NASH) models in mice. *Alcohol Clin Exp Research* 33(10):1704-1710.
92. Chang S, Kodys K, **Szabo G**. 2010. Impaired expression and function of Toll-like receptor 7 in Hepatitis C Virus infection in human hepatoma cells. *Hepatology* 51(1):35-42.
93. Velayudham A, Hritz I, Catalano D, Mandrekar P, Dolganiuc A, Csak T, Kurt-Jones E, **Szabo G**. 2009. Impaired lipopolysaccharide recognition via TLR4 and MD-2 deficiency attenuates non-alcoholic steatohepatitis and fibrosis in mice. (Under review.)

#### **Proceeding of Meetings:**

1. Miller-Graziano C, **Szabo G**, et al: 1989. Immunologic Consequences. In (Fiddian-Green R, Ed.) Splanchnic Ischemia and Multiple Organ Failure. Edward Arnold Co., Inc.,
2. Miller-Graziano C, **Szabo G**, Takayama T, Wu J: 1989. Alterations of MØ Function Following Major Surgery. In (Faist E., Ed.) The Immune Consequences of Trauma, Shock and Sepsis. Springer-Verlag, Berlin, Germany, pp. 95-109. Baltimore, pp. 237-247.
3. Miller-Graziano CL, **Szabo G**, Kodys K, et al: 1993. Interactions of Immunopathological Mediators (TNF- $\alpha$ , TGF- $\beta$ , PGE<sub>2</sub>) in Traumatized Individuals. In (Faist E., Ed.) Host Defense Dysfunction in Trauma, Shock and Sepsis. Springer-Verlag, Berlin, Germany, pp. 637-650.
4. **Szabo G**, Mandrekar P, Verma B, Catalano D: 1996. Acute Ethanol Uptake Prior to Injury Modulates Monocyte TNF Production and Mononuclear Cell Apoptosis. In (Faist E., Ed.) Host Defense Dysfunction in Trauma, Shock and Sepsis. Springer-Verlag, Berlin, Germany, pp. 252-260.
5. **Szabo G**, Mandrekar P: 2000. Ethanol and NF- $\kappa$ B signaling in immune cells. In (Zakhari, Ed.) Ethanol and Intracellular Signaling. NIAAA Monograph 35 pp 119-134.

6. Thiele G and **Szabo G**: 2002. Modulation of Immunity and Viral-Host Interactions by Alcohol. *Alcoholism: Clin. Exp. Res.* 26:1897-1908.
7. Thiele GM, Mandrekar P, Zakhari S, Joek J, Cook RT, Ray N, Happel KI, Kolls JK, Kovacs EJ, **Szabo G**. 2005. RSA 2004: Combined Basic Research Satellite Symposium—Mechanism Of Alcohol-Mediated Organ And Tissue Damage: Inflammation And Immunity And Alcohol And Mitochondrial Metabolism: At The Crossroads Of Life And Death. Session One: Alcohol, Cellular And Organ Damage. *Alcohol Clin Exp Res.* 29(9):1735-1743.
8. Mandrekar P, Pruetz S, Arteel G, Thiele G, **Szabo G**. 2005. RSA 2004: Combined Basic Research Satellite Symposium – Session Two: Toll-Like Receptors and Organ Damage. *Alcohol: Clin Exp Res.* 29(9):1744-1748.
9. **Szabo G**, Hoek JB, Darley-Usmar V, Hajnoczky G, Knudson T, Mochly-Rosen D, Zakhari S. 2005. RSA 2004: Combined Basic Research Satellite Symposium – Session Three: Alcohol and Mitochondrial Metabolism: At the Crossroads of Life and Death. *Alcohol Clin Exp Res.* 29(9):1749-1752.
10. **Szabo G**, Weinman SA, Gao B, Polyak SJ, Mandrekar P, Thiele GM. 2005. RSA 2004: Combined Basic Research Sattelite Symposium – Session Four: Hepatitis Virus and Alcohol Interactions in Immunity and Liver Disease. *Alcohol Clin Exp Res.* 2005; 29(9):1753-1757.
11. **Szabo G**, LPS in Liver Disease. III Falk Symposium, Mainz, Germany (in press)
12. **Szabo G**, Toll-like Receptors in the Liver, MTA Publications, Budapest (in press)

#### Book Chapters/Review Articles:

1. **Szabo G**. 1993. Monocyte-mediated Immunodepression after Acute Ethanol Exposure in Alcohol, Drugs of Abuse and Immunomodulation (AIDS). In Advances in Biosciences. Vol. 86. Ed: R.R. Watson, Philadelphia, Pergamon Press, pp. 121-130.
2. **Szabo G**. 1994. Production in human lymphoid and myeloid cells by alcohol in vitro. In (Watson, R.R., Ed.) Alcohol, Drugs of Abuse and Immune Function, (Edition 2), CRC Press, pp 105-119.
3. **Szabo G**, Romics L, Frenzl G. 2002. Liver in sepsis and systemic inflammatory response syndrome. In Hepatic Manifestations of Systemic Diseases, Ed. H.L. Bonkovsky Clinics in Liver Disease. 6:1045-1066. Publisher: W.B. Saunders, Philadelphia.
4. **Szabo G**. 2003. Pathogenic interactions between alcohol and hepatitis C. *Current Gastroenterology Reports.* 5:86-92.
5. **Szabo G**, Dolganiuc A. 2005. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic hepatitis C virus infection. *Immunobiology* 210(2-4):237-247.
6. Romics L, Jr., **Szabo G**, Coffey J C, Wang J H, Redmond H P. 2006. The emerging role of Toll-like receptor pathways in surgical diseases. *Arch Surg* 141:595-601.
7. **Szabo G**, Dolganiuc A, Mandrekar. 2006. Pattern recognition receptors: A contemporary view on liver diseases. *Hepatology* 44(2):287-298.
8. **Szabo G**, Dolganiuc A. Immunologic marker analysis of cells in the various stages of hematopoietic differentiation. In: Clinical Applications of Immunophenotypic Analysis. Editor: K. Paloczi, R.G. Landes Co., Publisher (in press).
9. **Szabo G**. Dolganiuc A, Chang S. 2007. Altered Innate Immunity in Chronic Hepatitis C Infection – Cause or Effect? *Hepatology* 46:1279-1290.

10. **Szabo G**, Mandrekar P, Dolganiuc A. 2007. Innate Immune Response and Hepatic Inflammation. *Semin Liver Disease* 27(4):339-350.
11. **Szabo G**, Dolganiuc A. 2008. Editorial. Hepatitis C core protein – The “core” of immune deception? *J Hepatology* 48(1): 8-11.
12. **Szabo G**, Dolganiuc A. 2008. The role of plasmacytoid dendritic cell-derived IFN $\alpha$  in antiviral immunity. In: *Critical Reviews in Immunology* 28(1):61-94. Review.
13. **Szabo G**, Mandrekar P. 2008. Human monocytes, macrophages and dendritic cells: alcohol treatment methods. *Methods in Molecular Biology* 447:113-124.
14. Dolganiuc A, **Szabo G**. 2008. T cells with regulatory activity in hepatitis C virus infection: what we know and what we don't. *J Leukoc Biol.* 84(3):614-622.
15. **Szabo G**, Dolganiuc A. Hepatitis C and Innate Immunity: Recent Advances. 2008. In: *Clin Liver Disease* 12(3):675-692.
16. **Szabo G**. The “Health” and Future of the Physician-Scientist in Hepatology. Special Article. 2009. *Hepatology* 49(2)341-343.
17. **Szabo G**, Mandrekar P. A Recent Perspective on Alcohol, Immunity, and Host Defense. 2009. *Alcohol Clin Exp Res* 33(2):220-232.
18. Mandrekar P, **Szabo G**. Signaling Pathways in Alcohol-Induced Liver Inflammation, 2009. *J Hepatology* 50(6):1258-1266.
19. Lau AH, **Szabo G**, Thomson AW. Antigen-presenting cells under the influence of alcohol. 2009. *Trends Immunol* 30(1):13-22.
20. **Szabo G**, Mandrekar P. Toll-like Receptors. 2010. *Signaling Pathways in Liver Diseases* 8:149-159.
21. Nath B, **Szabo G**. Alcohol-induced Modulation of Signaling Pathway in Liver Parenchymal and Nonparenchymal Cells: Implications for Immunity. 2009. *Seminars in Liver Disease* 29(2):166-177.

#### **Abstracts:**

**All abstracts listed below were presented at the Annual Meetings of the representative societies.**

**\* denotes oral presentation/award**

1. **Szabo G**, Frenzl G, et al. 1986. Abnormal Cytotoxic Activity of Polymorphonuclear Leukocytes in Autoimmune Diseases. 6th International Congress of Immunology, Toronto, Canada, p. 417.
2. Frenzl G, **Szabo G**, et al. 1986. Granulocyte Aggregation and Active Radical Production in Systemic Lupus Erythematosus (SLE) and Mixed Connective Tissue Disease. 6th International Congress of Immunology, Toronto, Canada, p. 417.
3. **Szabo G**, Wu J, Miller-Graziano C. 1987. Differential Monokine Production by Human M $\phi$  Subsets. International Workshop on Monokines and Other Non-Lymphocytic Cytokines. *Journal of Leukocyte Biology*, 42:585.
4. Wu J, **Szabo G**, Miller-Graziano C, Kodys K. 1988. MDP Inhibition of M $\phi$  Subset Plasminogen Activator. *The FASEB Journal*, 2:A1451.
5. Miller C, **Szabo G**, Takayama T. 1988. Interleukin-4 (IL-4) Effects on Monocyte PGE $_2$  and Tumor Necrosis Factor (TNF). *Journal of Leukocyte Biology*, 44:273.

6. **Szabo G**, Miller C, Wu J, Kodys K. 1988. Characteristics of Human CD4 Monocyte (MØ) Subsets. *Journal of Leukocyte Biology*, 44:276.
7. Wu J, **Szabo G**, et al. 1989. Elevated TGF $\beta$  Production by Trauma Patients' Monocytes (MØ). 7th International Congress of Immunology, Berlin, West Germany, p. 907.
8. Miller D, **Szabo G**, Kodys K. 1989. TGF $\beta$  Modulates MØ Secretion of TNF. 7th International Congress of Immunology, Berlin, West Germany, p. 427.
9. **Szabo G**, Kodys K, Miller C. 1989. FcRI<sup>+</sup> Monocyte MØ) Subset Produces the Majority of MØ IL-6. 7th International Congress of Immunology, Berlin, West Germany, p. 906.
10. **Szabo G**, Kodys K, Miller C. 1989. Mechanisms for Interleukin (IL-6) Induction in Human Monocytes. *Journal of Leukocyte Biology*, p. 309.
11. Miller C, **Szabo G**, Kodys K. 1989. Elevated IL-6 Production by Immunosuppressed Trauma Patients' Monocytes (MØ). *Journal of Leukocyte Biology*, p. 323.
12. **Szabo G**, Miller CL. 1989. Monokine Induction by Fc $\gamma$  Type I Receptor Crosslinking. *Cytokines*, 1:87.
13. Miller C, **Szabo G**, Kodys K: 1989. LTB<sub>4</sub> Negatively and Positively Modulates MØ TNFa Production. *Cytokines*, 1:113.
14. **Szabo G**, Kodys K, Miller C. 1990. Anti-inflammatory Regulation of Post-Trauma Monocytes by IL-4. *FASEB Journal*, 4(7):A1768.
15. **Szabo G**, Miller C. 1990. Ethanol Induced Aberrations in Monokine Production by Trauma Patients' Monocytes. *Alcoholism: Clin Exp Res*, 14(2):343.
16. Miller C, **Szabo G**. 1990. Modulation of Post-Trauma Monocytes (MØ) Functions by Novel Yeast Carbohydrates. *Proceedings Congress Infectious Disease*, 1:7.
17. Miller-Graziano CL, **Szabo G**, Kodys K. 1990. Anti-inflammatory Regulation of Post-Trauma Monocyte by IL-4. *Lymphokine Research*, 9:611
18. **Szabo G**, Kodys K, Miller-Graziano CL. 1990. Mechanisms for IL-6 Downregulation by IL-4 in Human Monocytes (MØ). *Lymphokine Research*, 9:590.
19. **Szabo G**, Fogarasi M, Catalano D: 1991. Alteration of Monocyte TNFa IL-6, PGE<sub>2</sub> and TGFb Responses by Ethanol. *Alcoholism Clinical and Experimental Research*, 15:361.
20. **Szabo G**, Miller-Graziano C. 1991. Modulation of Surface Expression and Monokine Production by Cyclic AMP in Human Monocytes. *Journal of Leukocyte Biology* (2), p. 64.
21. Verma B, **Szabo G**: 1992. Acute Ethanol Treatment Downregulates Monocyte TNFa and IL-6 Production. 8th International Congress of Immunology, August 23-28, 1992, Budapest, Hungary.
22. **Szabo G**, Catalano D. 1992. Decreased Antigen Presentation and Monocyte IL-1 Production after Ethanol Treatment. 8th International Congress of Immunology, August 23-28, 1992, Budapest, Hungary.
23. **Szabo G**, Miller-Graziano C. 1992. Elevated Intracellular cAMP Levels Promote Monocyte Antigen Presentation Capacity. *Journal of Leukocyte Biology Supplement 3*, p. 45.
24. **Szabo G**. 1992. Potential Mechanisms of Ethanol-induced Decreased Antigen Presentation, *Journal of Leukocyte Biology. Supplement 3*, p. 32.

25. \*Mandrekar P, Verma B, Catalano D, **Szabo G**. 1994. Acute Ethanol Exposure Inhibits Superantigen-Induced IL-1-Beta and Augments TGF-Beta Production in Human Monocytes. 1994 Research Society on Alcoholism Annual Scientific Meeting, 6/18-23, 1994, Maui, Hawaii. *Alcoholism: Clinical and Experimental Research*, Vol. 18(2), April, p. 440.
26. **Szabo G**, Mandrekar P, Verma B, Catalano D. 1994. Decreased Superantigen-Induced T Cell Proliferation after Acute Ethanol Exposure - Possible Role of Decreased Monocyte TNF and HLA-DR Expression and Increased Apoptosis. 1994 Research Society on Alcoholism Annual Scientific Meeting, 6/18-23, 1994, Maui, Hawaii. *Alcoholism: Clinical and Experimental Research*, Vol. 18(2), April, p. 440.
27. **Szabo G**, Verma B, Mandrekar P, Catalano D. 1994. Acute Ethanol Uptake Prior to Injury Modulates Monocyte TNF $\alpha$  Production and Mononuclear Cell Apoptosis. *Intensive Care Medicine*. 20, Suppl. 1 (page S82).
28. Mandrekar P, Catalano D, **Szabo G**. 1994. Monocyte (M $\phi$ ) IL-10 Induction and Its Regulatory Effects after Acute Alcohol Exposure. *Journal of Leukocyte Biology*, Supplement 1994, p. 36.
29. **Szabo G**, Mandrekar P, Catalano D; 1995. Induction of IL-10 in Human Monocyte by Acute Ethanol Exposure. *Immunological Consequences*. *Alcoholism*, Suppl 19 (2) p.23A.
30. \*Mandrekar P, Maciaszek J, Viglianti G, **Szabo G**. 1995. Regulation of NF-KB by Ethanol Treatment in Monocytes. *Journal of Leukocyte Biology*. Suppl p. 21.
31. **Szabo G**, Mandrekar P, Newman L, Catalano D. 1995. Modulation of Monocyte Inflammatory Response by Acute Ethanol Exposure. *Journal of Leukocyte Biology*. Suppl p. 24.
32. **Szabo G**, Mandrekar P, Catalano D. 1995. Inhibition of Superantigen-Induced T Cell Proliferation and Monocyte IL-1 $\alpha$  TNF $\alpha$  and IL-6 Production by Acute Ethanol Treatment. *Journal of Leukocyte Biology*. 58:342-350.
33. Mandrekar P, Catalano D, **Szabo G**. 1995. Human Monocyte IL-10 Production is Increased by Acute Ethanol Treatment. *Cytokines*.
34. **Szabo G**, Mandrekar P, Newman L, Catalano D. 1995. Regulation of Human Monocyte Functions by Acute Ethanol Treatment: Decreased TNF $\alpha$ , IL-1 $\alpha$  and Elevated IL-10, TGF $\beta$  Production. *Alcoholism: Clin. Exp. Res.* 20:900-908.
35. **Szabo G**, Girouard L, Mandrekar P, Catalano D. 1996. IL-12 Induction by Alcohol and its Regulation by IL-10 in Human Monocytes. *Journal of Leukocyte Biology*. Suppl. p. 19.
36. \*Mandrekar P, Maciaszek J, Catalano D, Viglianti G, **Szabo G**. 1996. Regulation of NFkB by ethanol in monocytes. *Alcoholism: Clin. Exp. Res.* 20:117A
37. **Szabo G**, Newman L, Mandrekar P, Catalano D. 1996. Ethanol-induced regulation of IL-12 and IL-10 production. *Alcoholism: Clin. Exp. Res.* 20:117A.
38. Newman L, Mandrekar P, Catalano D, **Szabo G**. 1996. Heat shock protein induction by ethanol in monocytes. *Alcoholism: Clin. Exp. Res.* 20:117A.
39. Mandrekar P, Catalano D, **Szabo G**. 1997. Differential NFkB/Rel complex induction by ethanol versus LPS in human monocytes. *Alcoholism: Clin. Exp. Res.* 21:47A.
40. \***Szabo G**, Mandrekar P, Catalano D. 1997. Decreased IL-12 and elevated IL-10 production by the human monocyte subpopulation expressing FC $\gamma$ RI. *J. Leuk. Biol. Supplement*, 82:20.
41. \*Mandrekar P, Catalano D, **Szabo G**. 1997. LPS-induced NF-kB is prevented by acute ethanol treatment in human monocytes. *J. Leuk Biol. Supplement*, 119:27.

42. Mandrekar P, Catalano D, **Szabo G**. 1998. Ethanol-induced regulation of NF $\kappa$ B in monocytes (M $\emptyset$ ). 10th International Congress of Immunology, New Delhi, India.
43. \***Szabo G**, Mandrekar P, Catalano D. 1998. Acute alcohol regulation of inflammatory cytokine production in human monocytes: A role for NF-kB. Digestive Disease Week, New Orleans, LA
44. **Szabo G**, Mandrekar P, Catalano D. 1998. Immune alterations after acute alcohol consumption in humans. Alcoholism: Clin. Exp. Res. 22:21A.
45. Chavan S, Mandrekar P, Catalano D, **Szabo G**. 1998. Downregulation of chemokines by acute ethanol treatment in human peripheral blood mononuclear cells. Alcoholism: Clin. Exp. Res. 22:21A.
46. **Szabo G**, Mandrekar P, Catalano D. 1999. Acute alcohol intake alters innate and adoptive monocyte functions in humans. J. Leuk. Biol. Supplement, p. 28.
47. **Szabo G**, Chavan S, Mandrekar P, Catalano D. 1999. Decreased IL-8 and MCP-1 induction after alcohol: A potential role for NF-kB. Alcoholism: Clin. Exp. Res. Supplement.
48. **Szabo G**, Mandrekar P, Bellerose G, Catalano. 2000. IFN $\gamma$  and ethanol augment NF-kB activation in HepG2 cells and modulate regulatory and inflammatory cytokine production in human monocytes. Hepatology 30: Suppl. p 374A
49. Karuri AR, **Szabo G**. 2000. Increased NF- $\kappa$ B activation by alcohol in Con-A hepatitis in obese but not in lean mice. J. Leuk. Biol. Supplement, p. 27.
50. \*Drechsler Y, Mandrekar P, Chavan S, **Szabo G**. 2000. NF $\kappa$ B activation in FcR crosslinked human monocytes correlates with induction of TNF $\alpha$  and inhibition of IL-12. J. Leuk. Biol. Supplement, p. 13.
51. Mandrekar P, Bellerose G, **Szabo G**. 2000. Effect of acute alcohol treatment on glucocorticoid receptor function. J. Leuk. Biol. Supplement, p. 15.
52. **Szabo G**, Gavala C. 2000. Decreased allostimulatory capacity of myeloid dendritic cells after tacrolimus or Cyclosporin A treatment. J. Leuk. Biol. Supplement, p. 27.
53. **Szabo G**, Mandrekar P. 2001. Alcohol Consumption Impairs Antigen-Specific T Cell Activation: The Role of Monocytes and Dendritic Cells. Gastroenterology 120:Suppl#1.p. A554
54. \*Dolganiuc A, Kodys K, Kopasz A, Mandrekar P, **Szabo G**. 2001. Inhibition of IL-12 production by hepatitis C viral proteins correlates with reduced APC function of dendritic cells from HCV infected patients. J. Leuk. Biol. Supplement, p. 70.
55. Mandrekar P, Catalano D, **Szabo G**. 2001. Increased IL-10 and decreased IL-12 production correlate with reduced antigen presentation in alcohol-exposed myeloid dendritic cells. J. Leuk. Biol. Supplement, p. 86.
56. \***Szabo G**, Dolganiuc A, Kopasz A, Mandrekar P, Kodys K. 2002. Impaired Allostimulatory Capacity of Myeloid Dendritic Cells of Patients with Chronic Hepatitis C is reproduced by Core and NS3 Proteins and Further Reduced by Alcohol. Digestive Disease Week - 2002; May 19-22, 2002, San Francisco, CA.
57. \*Romics L Jr, Mandrekar P, Kodys K, **Szabo G**. 2002. Diverse activation of NF $\kappa$ B and PPRE binding in a mouse model of non-alcoholic fatty liver after LPS and alcohol stimulation. Digestive Disease Week - 2002; May 19-22, 2002, San Francisco, CA.
58. **Szabo G**, Dolganiuc A, Kodys, K, Romics L, Mandrekar P. 2002. Inhibition of NF- $\kappa$ B by acute alcohol is common to monocyte activation through CD14/TLR4, IL-1- or TNF-receptor and it is independent of

- I $\kappa$ B degradation. 7<sup>th</sup> Conference of the International Endotoxin Society; July 18-21, 2002, Washington, DC and published in J. Endotoxin Research 8(3):187; Abstract #96.
59. Romics L, **Szabo G**. 2002. Differential regulation of TLR2 and TLR4 mRNA by endotoxin in normal, alcoholic, and non-alcoholic fatty livers. 7<sup>th</sup> Conference of the International Endotoxin Society; July 18-21, 2002, Washington, DC and published in J. Endotoxin Research 8(3):193; Abstract #113.
  60. Dolganiuc A, Kodys K, Kopasz A, Mandrekar P, **Szabo G**. 2002. Alcohol inhibits the already impaired myeloid dendritic cell functions via increased IL-10 and reduced IL-12 in patients with chronic hepatitis C infection Research Society of Alcoholism Meeting, June 28-July3.
  61. \*Dolganiuc A, Mandrekar P, Zapp M, **Szabo G**. 2002. Hepatitis C core and NS3 proteins are internalized by human monocytes, activated pro-inflammatory pathways via nuclear factor- $\kappa$ B, and induce immunoinhibitory cytokine production. 53<sup>rd</sup> Annual Liver Meeting, November 1-5, 2002, Boston, MA and published in Hepatology AASLD 36(4); 268A; Abstract #422.
  62. Romics L, Drechsler Y, **Szabo G**. 2002. Inhibition of TNF $\alpha$  production by S-adenosylmethionine is mediated via inhibition of NF- $\kappa$ B binding and I $\kappa$ B $\alpha$  Degradation and does not involve IL-10 induction. 53<sup>rd</sup> Annual Liver Meeting, November 1-5, 2002, Boston, MA and published in Hepatology AASLD 36 (4); 328A; Abstract #660.
  63. Romics L, Kodys K, Golenbock D, **Szabo G**. 2002. The role of toll-like receptor 2 in increased liver injury after Propionibacterium acnes priming. 53<sup>rd</sup> Annual Liver Meeting, November 1-5, 2002, Boston, MA and published in Hepatology AASLD 36 (4); 329A; Abstract #665.
  64. \***Szabo G**, Dolganiuc A, Kodys K. 2002. Hepatitis C core and NS3 but not E2 proteins activate human monocytes and inhibit myeloid dendritic cell differentiation 2<sup>nd</sup> Macrophage study Society Meeting, Bazel, Switzerland.
  65. \*Dolganiuc A, Kodys K, Kurt-Jones E, Golenbock D, **Szabo G**. 2003. Hepatitis C core and NS3, but not E2, proteins activate pro-inflammatory pathways via pattern recognition receptor, Toll-like receptor 2. (#509) DDW 2003, May 17-22, Orlando, FL. Gastroenterology 124 (4): A715-A715 Suppl. S APR 2003.
  66. Romics L, Kodys K, Li W, Dolganiuc A, **Szabo G**. 2003. Propionibacterium acnes sensitizes the liver for Toll-like receptor 4, but not for TLR2 mediated injury involves up-regulation of the TLR4/MD-2 receptor complex. S885, Gastroenterology 124 (4): A720-A720 Suppl. DDW, May 17-22, Orlando, FL.
  67. Romics L, Kodys K, Golenbock D, **Szabo G**. 2003. Propionibacterium Acnes triggers inflammatory responses via Toll-like receptor and sensitizes for liver injury via TLR2-independent pathways. S885 Gastroenterology 124 (4) DDW, May 17-22, Orlando, FL.
  68. \*Dolganiuc A, Kodys K, Kopasz A, Marshall C, Do T, Romics L, Zapp M, **Szabo G**. 2003. Hepatitis C core and NS3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cells differentiation. FASEB J 17 (7): C255-C256 Suppl. AAI Meeting, May 8, 2003 Denver, CO
  69. \*Romics L, Kodys K, Dolganiuc A, **Szabo G**. 2003. Diverse regulation of NF- $\kappa$ B and PPARs in non-alcoholic fatty liver disease in mice. 45<sup>th</sup> Annual Meeting of the Hungarian Society of Gastroenterology, Balatonaliga, June 3-7, Hungary.
  70. \*Romics Jr. L, Velayudham A, Dolganiuc Angela, Li W, **Szabo G**. 2003. Up-regulation of MD-2 in LPS hypersensitive livers in mice. Irish Society of Immunology Annual Scientific Meeting, September 18-19.
  71. \*Dolganiuc A, Kodys K, Kopasz A, **Szabo G**. 2003. Hepatitis C virus core and NS3 proteins trigger TLR2 and impair differentiation of monocyte-derived dendritic cells. 36<sup>th</sup> Annual SLB Meeting,

October 2-5, Philadelphia, PA.

72. \*Romics Jr. L, Kodys K, Dolganiuc A, Mandrekar P, Golenbock D, **Szabo G** . 2003. Distinct roles for TLR2 and TLR4 in liver sensitization. 36<sup>th</sup> Annual SLB Meeting, October 2-5, Philadelphia.
73. Velayudham A, Romics L, Kodys K, Li W, Szabo G. 2003. LPS sensitivity is associated with reduced peroxisome proliferator response element activation in fatty liver. J. Leuk Biol. Suppl. 2003. 36<sup>th</sup> Annual Meeting of the Society for Leukocyte Biology, October 21-23, Philadelphia, PA.
74. \***Szabo G**, Romics L, Kodys K, Dolganiuc A, Mandrekar P, Golenbock D. 2003. Distinct roles for Toll-like receptor 2 (TLR2) and (TLR4 in liver sensitization and injury. 54<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28. Oral presentation #197. Hepatology 2003; 38 (4) Suppl 1.
75. \*Drechler Y, Romics L, Li W, **Szabo G**. Role of Heme Oxygenase-1 in alcohol mediated cytokine regulation. 54<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28. Poster presentation #842 – AASLD Presidential Poster of Distinction. Hepatology 2003; 38 (4) Suppl 1.
76. Dolganiuc A, Kodys K, Kopasz A, **Szabo G**. 2003. Pattern recognition of HCV core and NS3 proteins by innate immune cells: Role for TLR2 but not for TLR4. AASLD Meeting October 24-28, Boston MA
77. Mandrekar P, Bellerose G, Catalano D, **Szabo G**. 2003. Diverse regulation of NfkappaB Activation and TNF-alpha production after acute and chronic alcohol treatment in human monocytes. 54<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28. Poster presentation #930. Hepatology 2003; 38 (4) Suppl 1.
78. \*Velayudham A, Romics L, Kodys K, Dolganiuc A, Mandrekar P, Golenbock D. 2003. Increased pro-inflammatory activation by endotoxin is associated with attenuated PPRE activation in an animal model of NASH. Best Oral Presentation at Annual Conference 2003, American College of Physicians – MA Chapter, November, 2003.
79. Romics L, Velayadhum A, **Szabo G**: 2004. LPS hypersensitivity in the liver results in increased activation of the NF- $\kappa$ B pathway but Independent on TLR4 Levels. 24<sup>th</sup> Annual Meeting, Indianapolis, IN Surgical Infection Society April 29-May 1, 2004. Surgical Infections 2004 5(1): 109; abstract #109.
80. \*Oak S, Mandrekar P, Dolganiuc A, **Szabo G**. 2004. Distinct regulation of Toll like receptor (TLR) 2 and TLR4 mediated inflammatory responses by acute alcohol. Abstract #1958 DDW, May 15-20, , Morial Conventional Center, New Orleans, LA
81. \*Dolganiuc A, Velayudham A, Holla S, Mandrekar P, **Szabo G**. 2004. Loss of Circulating Plasmacytoid Dendritic Cells Correlates With Reduced Interferon Alpha Production in Chronic Hepatitis C Infection. Abstract #1935. DDW, May 15-20, New Orleans, LA
82. Velayudham A, Dolganiuc A, **Szabo G**. 2004. TLR2 deficiency increases liver damage in an animal model of Non-Alcoholic Steatohepatitis Abstract #1687 DDW, May 15-20, 2004, New Orleans, LA
83. \*Romics L, Velayudham A, Dolganiuc A, **Szabo G**: 2004. Upregulation of Toll-like Receptor 4 (TLR4)/MD-2 Complex in LPS Hypersensitive Livers in Mice. 46<sup>th</sup> Annual Meeting of the Hungarian Society of Gastroenterology, Balatonaliga, Hungary. June 1-5, 2004.
84. \*Dolganiuc A and **Szabo G**. 2004. HCV core and NS3, but not envelope proteins, reproduce dendritic cells defects found in patients with chronic Hepatitis C virus infection. The Henry M. and Lillian Stratton Basic Research Single Topic AASLD Conference, Immunovirology and the Liver, June 11-13, Warrenton, VA.



85. Dolganiuc A, Kodys K, Bakis G, Golenbock D, Kurt-Jones E, **Szabo G**. 2004. TLR2, not CD14 and TLR4, is involved in innate immune activation by HCV core and NS3 proteins. 12<sup>th</sup> International Congress of Immunology and 4th Annual Conference of FOCIS, July 18-23, Montreal, Canada.
86. Oak S, and **Szabo G**. 2004. The complexity of TLR-mediated signals determine attenuation or augmentation of inflammation by alcohol: Role of IRAK, ERK and INK kinases. 55<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases, October 29-November 2, Boston, MA. Abstract #248. *Hepatology* 2004; 40 (4) Suppl 1.
87. Dolganiuc A, Oak S, Kodys K, Golenbock D, Kurt-Jones E, **Szabo G**. 2004. TLR2-mediated monocyte activation by HCV core and NS3 proteins involves the map kinases and NFKB pathway. 55<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases, October 29-November 2, Boston, MA. Abstract #545. *Hepatology* 2004; 40 (4) Suppl 1.
88. Velayudham A, Ellis M, **Szabo G**. Reduced IL-6 and IL-10 levels correlate with increased liver damage, NFKB and AP-1 activation after VSL#3 treatment in experimental NASH. 55<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases, October 29-November 2, Boston, MA. Abstract #602. *Hepatology* 2004; 40 (4) Suppl 1.
89. **Szabo G** and Dolganiuc A. HCV core indirectly induces plasmacytoid dendritic cell apoptosis and reduced IFN $\alpha$  production via monocyte activation. Hepatitis Single Topic Conference. March 4-5, 2005, Chicago, IL.
90. **Szabo G** and Dolganiuc A. HCV core protein-induced monocyte TNF-alpha and IL-10 mediate reduced IFN $\alpha$  production and increased apoptosis of plasmacytoid dendritic cells. 40<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver, April 13-17 2005, Paris, France.
91. Chang S and **Szabo G**. TLR co-receptors, TLR 1 and 6, both participate in TLR2 innate immune activation by HCV core and NS3 proteins. Hepatitis Single Topic Conference. March 4-5, 2005, Chicago, IL.
92. Dolganiuc A, Bakis G, Kodys K, Szabo G. Hepatitis C virus core protein-induced, Monocyte-mediated mechanisms of reduced IFN $\alpha$  and plasmacytoid dendritic cells loss in patients with chronic HCV infection. 5<sup>th</sup> Annual Conference of FOCIS, May 12-16, 2005, Boston, MA
93. Velayudham A, Romics L Jr, Dolganiuc A, Kodys K, Mandrekar P, Golenbock D, Kurt-Jones E, **Szabo G**. Role of Toll-Like Receptors 2 and 9 in induction of sensitization to lipopolysaccharide-induced liver injury by *Propionibacterium acnes*. *Gastroenterology* 2005; 128 (4) Suppl 2.
94. Dolganiuc AA, Kodys K, Thamma K, Bakis G, Jeliaskova V, Mandrekar P, Golenbock D, Kurt-Jones E, **Szabo G**. In vivo reprogramming results in loss of Toll-like receptor (TLR)2- and TLR4- mediated homo- and hetero-tolerance in patients with chronic hepatitis C infection. *Gastroenterology* 2005; 128(4) Suppl. 2.
95. **Szabo G** and Dolganiuc A. HCV core protein-triggered monocyte-derived cytokines lead to plasmacytoid dendritic cell death via apoptosis and impaired IFN $\alpha$  production in patients with chronic hepatitis C infection. *Gastroenterology* 2005; 128 (4) Suppl 2.
96. Dolganiuc A, Bakis G, Kodys K, **Szabo G**. Acute ethanol treatment modulates Toll-like receptor 4 association with lipid rafts. (#P204) 28<sup>th</sup> Annual Meeting of the Research Society on Alcoholism, June 25-June 30, 2005-Santa Barbara, CA.
97. Mandrekar P, Catalano D, Jeliaskova V, Kodys K, **Szabo G**. TNF $\alpha$  production is suppressed by acute alcohol, but increased by chronic alcohol exposure in human monocytes: Role for Nf $\kappa$ B and ERK activation. (#P788) 28<sup>th</sup> Annual Meeting of the Research Society on Alcoholism, June 25-30, 2005 Santa Barbara, CA.

98. **Szabo G** and Dolganiuc A. Pathogenic interactions between hepatitis C virus and alcoholic use in human Dendritic cells as common targets. (#S21) 28<sup>th</sup> Annual Meeting of the Research Society on Alcoholism, June 25-30, 2005-Santa Barbara, CA.
99. **Szabo G** and Mandrekar P. Alteration of the cytokine profile of circulating monocytes impacts dendritic cell differentiation and T cell activation after alcohol intake. (#S122) 28<sup>th</sup> Annual Meeting of the Research Society on Alcoholism, June 25-30, 2005-Santa Barbara, CA.
100. Dolganiuc A and Szabo G. Loss of Toll-like receptor mediated tolerance in patients with chronic hepatitis C infection. Submitted to 28<sup>th</sup> Annual Society of Leukocyte Biology Meeting, October 21-23, 2005, England.
101. Velayudham A, Dolganiuc A, Romics L, Mandrekar P, **Szabo G**. Induction of liver granulomas and sensitization to Toll-like receptor (TLR) 4-induced liver injury is dependent on the common TLR adaptor molecule, MyD88. (Accepted for oral presentation at: 56<sup>th</sup> Annual Meeting, AASLD, San Francisco, CA, November, 2005)
102. Velayudham A, Ellis M, Dolganiuc A, **Szabo G**. Probiotic treatment attenuates fibrosis but not steatosis or inflammatory pathway activation in diet-induced NASH. Submitted to 56<sup>th</sup> Annual Liver Meeting, AASLD, San Francisco, CA, November, 2005.
103. Dolganiuc A, Chang S, Mehta S, Shick L, Cormier M, Bombard D, Giansiracusa D, **Szabo G**. HCV-induced, Toll-like receptor 2 (TLR2)-mediated induction of TNF $\alpha$  and IL-10 inhibits IFN $\gamma$  production in patients with chronic hepatitis C infection. Submitted to 56<sup>th</sup> Annual Liver Meeting AASLD 2005, San Francisco, CA.
104. Mandrekar P, Catalano D, Jeliaskova V, Kodys K, **Szabo G**. 2005. TNF $\alpha$  production is suppressed by acute alcohol but increased by chronic alcohol exposure in human monocytes: role for NF $\kappa$ B and ERK activation. *Alcoholism: Clin. Exp. Res.* 29(5); p139A.
105. **Szabo G**, and Mandrekar P. 2005. Alteration of the cytokine profile of circulating monocytes impacts dendritic cell differentiation and T cell activation after alcohol intake. *Alcoholism: Clin. Exp. Res.* 29(5); p193A.
106. Romics Jr L., Dolganiuc A, Kodys K, Golenbock D, **Szabo G**. "Role of Toll-like receptor (TLR) 2 and CD14 in sensitization to TLR4-mediated liver injury. Annual Meeting of Society of Academic and Research Surgery 2005, Kork, Ireland. (Published in *British Journal of Surgery* 91(9):1226)
107. Mandrekar P, Catalano D, Dolganiuc A, and **Szabo G**. In-vitro and In vivo alcohol consumption decreases antigen-presentation capacity of myeloid dendritic cells and contributes T cell anergy. Annual Meeting of the American Association of Immunology, May 2006, Boston, MA
108. \***Szabo G** and Dolganiuc A, "HCV core protein-induced monocyte TNF-alpha and IL-10 mediate reduced IFN $\alpha$  production and increased apoptosis of plasmacytoid dendritic cells" 40<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver, April 13-17, 2005, Paris, France
109. \*Dolganiuc A, Bakis G, Kodys K, **Szabo G** Hepatitis C virus core protein-induced, monocyte-mediated mechanisms of reduced IFN $\gamma$  and plasmacytoid dendritic cells loss in patients with chronic HCV infection. 5th Annual Conference of FOCIS, May 12-16, 2005 Boston, MA.
110. Dolganiuc A, Thamma K, Bakis G, Kodys K and **Szabo G**. "HCV core indirectly induced plasmacytoid dendritic cells apoptosis and reduced IFN $\gamma$  production via monocyte activation." Hepatitis Single Topic AASLD Conference, March 2-3, 2005, Chicago, IL.
111. Dolganiuc A, **Szabo G** "Loss of Toll-like receptor mediated tolerance in patients with chronic hepatitis C infection. 38<sup>th</sup> Annual Society of Leukocyte Biology Meeting, October 21-23, 2005, England.

112. \*Dolganiuc A, **Szabo G**. "HCV protein-induced defects of plasmacytoid dendritic cells in patients with chronic hepatitis C infection." 2<sup>nd</sup> International Conference on Dendritic Cells at the Host-Pathogen Interface, September 26-29, 2005, Arlie, Virginia.
113. \***Szabo G**, Dolganiuc A. "Toll-like receptor (TLR) 2-mediated subversion of plasmacytoid dendritic cell functions in hepatitis C." 12<sup>th</sup> International Symposium on Hepatitis C Virus and Related Viruses, October 2-6 2005, Montréal (Canada).
114. Dolganiuc A, Chang S, Mehta S, Shick L, Cormier M, Bambard D, Giansaracusa D, **Szabo G**. "HCV-induced, Toll-like receptor 2 (TLR2)-mediated induction of TNF $\alpha$  and IL-10 inhibits IFN $\gamma$  production in patients with chronic hepatitis C infection" The 56<sup>th</sup> Annual Liver meeting AASLD 2005, November 11-15, 2005, San Francisco CA.
115. Velayudham A, Ellis M, Dolganiuc A, **Szabo G**. "Probiotic treatment attenuates fibrosis but not steatosis or inflammatory pathway activation in diet-induced NASH" The 56<sup>th</sup> Annual Liver meeting AASLD 2005, November 11-15, 2005, San Francisco CA
116. \*Velayudham A, Dolganiuc A, Romics L, Mandrekar P, **Szabo G**. "Induction of liver granulomas and sensitization to Toll-like receptor (TLR) 4-induced liver injury is dependent on the common TLR adapter molecule, MyD88" The 56<sup>th</sup> Annual Liver meeting AASLD 2005, November 11-15, 2005, San Francisco CA.
117. Dolganiuc A, Bakis G, Kodys K, **Szabo G**. "Acute ethanol modulates partitioning of LPS-induced receptor cluster into lipid rafts". Annual AIRIG meeting, November 18<sup>th</sup>, 2005, Chicago, IL 2005 (travel award from AIRIG).
118. Mandrekar P, Catalano D, Jeliaskova V, Wang A and **Szabo G**. Differential Induction of heat shock protein 70 and 90 by acute and chronic alcohol treatment of murine macrophages correlates with alterations in inflammatory cytokine production. International Symposium on Alcoholic Liver and Pancreatic diseases and Cirrhosis. May 2006, Los Angeles, CA.
119. Mandrekar P, Catalano D, Dolganiuc A, **Szabo G**. Alcohol intake decreases antigen-presentation capacity of myeloid dendritic cells and contributes to T cell anergy. *Alcoholism: Clin. Exp. Res.* 30(6); p 171A.
120. Mandrekar P, Catalano D, Jeliaskova V, Wang A, **Szabo G**. Alcohol exposure affects inflammatory cytokine production through interactions of NF $\kappa$ B, heat shock transcription factor and heat shock proteins in RAW 264.7 macrophages. *Alcoholism: Clin. Exp. Res.* 30(6); p 222A.
121. Hritz I, Velayudham A, Mandrekar P, **Szabo G**. MyD88-independent but Toll-like receptor 4 (TLR4) dependent pathways mediate liver injury in mice after chronic alcohol feeding. Digestive Disease Week, May 20-25, 2006, Los Angeles, CA.
122. Velayudham A, Hritz I, **Szabo G**. Deficiency in the expression of Toll-like receptor 4, its co-receptor, MD-2, or the TLR adapter, MyD88, provides protection against diet-induced steatohepatitis and fibrosis. Digestive Disease Week, May 20-25, 2006, Los Angeles, CA.
123. Hritz I, Velayudham A, Mandrekar P, Kurt-Jones E, **Szabo G**. Protective role of Toll-like receptor 4- but not MyD88 deficiency in chronic alcohol induced liver damage in mice. 29<sup>th</sup> Annual Scientific Meeting of the Research Society on Alcoholism, June 23-29, 2006, Baltimore, MD.
124. \*Dolganiuc A, Bakis G, Kodys K, **Szabo G**. IFN- $\gamma$ -induced loss of TLR tolerance correlates with increased monocyte activation in chronic HCV infection. DDW 2006, May 20-25, Los Angeles Convention Center, Los Angeles, CA.

125. \*Mandrekar P, Catalano D, Dolganiuc A, **Szabo G**. In vitro and in vivo alcohol exposure decreases antigen-presentation capacity of myeloid dendritic cells and contributes to T cell anergy. DDW 2006, May 20-25, Los Angeles Convention Center, Los Angeles, CA.
126. \*Dolganiuc A, Oak S, Kodys K, Mandrekar P, **Szabo G**. Disruption of LPS receptor complex at the level of lipid rafts by alcohol correlates with reduced inflammatory cell activation. RSoA Annual Meeting, July 2006, Baltimore, MD (Junior Investigator Travel award from RSoA).
127. \*Dolganiuc A, **Szabo G**. "IFN-gamma-induced loss of TLR tolerance correlates with increased monocyte activation in chronic HCV infection" American Association of Immunologists Meeting 2006, Boston May 12-16.
128. \*Dolganiuc A, Drechsler Y, Norkina O, Romics L, Li W, Kodys K, Bach F, Mandrekar P, **Szabo G**. Heme-oxygenase-1 activation mediates the anti-inflammatory effects of acute alcohol via IL-10 induction in monocytes AASLD 2006.
129. Hritz I, Dolganiuc A, Velayudham A, Mandrekar P, Kurt-Jones E, **Szabo G**. Oxidative stress and excessive pro-inflammatory cytokine production are involved in sensitization to lipopolysaccharide-induced acute liver injury by synergistic activation of Toll-like receptor 2 and 9. AASLD 2006.
130. Norkina O, Dolganiuc A, Kodys K, Mandrekar P, **Szabo G**. Acute alcohol modulates LPS-induced cell activation via STAT3 activation to result in excessive IL-10 production. AASLD 2006.
131. Chang S and **Szabo G**. TLR2 Co-Receptors, TLR1 and TLR6, Selectively Participate in TLR2 Innate Immune Activation by HCV Core and NS3 Proteins AASLD: The Liver Meeting; Boston, MA 2006 (Poster Presentation).
132. Chang S and **Szabo G**. AASLD Hepatitis Single Topic Conference: Interferon & Ribavirin in Hepatitis C Virus Infection: Mechanisms of Response and Non-Response; Chicago, IL 2007; Diminished TLR7 Receptor Expression in HCV Replicating Cells (Oral and Poster presentation, Travel Award).
133. Chang S and **Szabo G**. Loss of TLR7 receptor expression in HCV viral infection as a potential mechanism to evade the innate immune system. AAI: Immunology 2007; Miami, FL 2007. (Poster presentation).
134. Dolganiuc A, Paek E, Fair J, **Szabo G**. IFN- $\gamma$  contributes to dendritic cell-mediated expansion of regulatory T cells during HCV infection. AAI: Immunology 2007 Miami FL, 2007.
135. Dolganiuc A, Paek E, Fair J, **Szabo G**. Type III IFNs (IFN- $\gamma$ ) induces dendritic cell-mediated expansion of regulatory T cells in chronic HCV infection. Digestive Disease Week, 2007, Washington, DC.
136. **Szabo G**, Dolganiuc A, Catalano D, Kodys K, P. Mandrekar. 2007. Opposite regulation of monocyte activation by acute and prolonged alcohol occurs at multiple levels of TLR4 signaling. Alcoholism: Clin. Exp. Res. 31(6); p 273A: Abstract # 97.
137. P. Mandrekar, Jeliakova V, **Szabo G**, Catalano D. 2007. Alcohol modulates TNF $\alpha$  production in macrophages interactions between NF $\kappa$ B and stress-regulated hsp70 and hsp90. Alcoholism: Clin. Exp. Res. 31(6); p 275A: Abstract # 106.
138. P. Mandrekar, Catalano D, Jeliakova V, **Szabo G**. 2007. Alcohol exposure regulates HSF1 and heat shock proteins 70 and 90 in murine macrophages: Implications in TNF $\alpha$  production. 2<sup>nd</sup> World Conference of Stress, Cell Stress Society International Congress on stress responses in biology and medicine. P 328: Abstract # 6C\_05\_S.

139. Velayudham A, Hritz I, Dolganiuc A, Kurt-Jones E, Catalano D, P. Mandrekar, **Szabo G**. 2007. Diet-induced steatohepatitis is prevented by MyD88 knockout phenotype but not by selective MyD88 deficiency in the bone-marrow derived cells in mice. *Hepatology* 46 (4 Suppl 1): p 258A: Abstract # 55.
140. Norkina O, Dolganiuc A, Kodys K, P. Mandrekar, **Szabo G**. 2007. Alcohol consumption induces expression of SOCS3 and SOCS1 and inhibits signaling via STAT3 and STAT1 pathways in human monocytes. *Hepatology* 46 (4 Suppl 1): p 258A: Abstract # 1020.
141. **Szabo G**, Velayudham A, Hritz I, Catalano D, Kurt-Jones E, Dolganiuc A, P. Mandrekar. 2008. Two faces of MyD88 expression in steatohepatitis: protection in liver parenchymal cells and mediation of damage in bone-marrow derived cells. *Hepatology* 48 (4 Suppl): p366A: Abstract #136.
142. **Szabo G**, Hritz I, Velayudham A, Nath B, Catalano D, Petrasek J, Kodys K, Kurt-Jones E, P. Mandrekar. 2008. A novel, critical role of interferon regulatory factor 3 in alcoholic liver disease. *Hepatology* 48 (4 Suppl): p373A: Abstract #152.
143. **Szabo G**, Hritz I, Velayudham A, Nath B, Catalano D, Kodys K, Kurt-Jones E, P. Mandrekar. 2009. TLR4-induced pathways mediate alcoholic liver disease via IRF3. *Alcoholism: Clin. Exp. Res.* 33(6):028.
144. Mandrekar P, Catalano D, Kodys K, **Szabo G**. 2009. Alcohol impairs innate immune cell activation: distinct role of MAP kinases. *Alcoholism: Clin. Exp. Res.* 33(6):097.
145. **Szabo G**, Mandrekar P, Velayudham A., Hritz I. 2009. LPS in liver disease. *Alcoholism: Clin. Exp. Res.* 33(6):190.
146. Mandrekar P, Bala S, Catalano D, Kodys K, **Szabo G**. 2009. IRAK-M is a central regulator of the opposite effects of acute and chronic alcohol exposure on LPS-induced inflammation in human monocytes. *Soc. Leuk. Biology*. Lisbon, Portugal.
147. Mandrekar P, Bala S, Catalano D, Kodys K, **Szabo G**. 2009. IRAK-M plays a central role in the differential regulation of acute and chronic alcohol exposure on LPS-induced inflammation in human monocytes. AIRIG meeting, Chicago, MA.
148. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, **Szabo G**. 2009. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced NASH model in mice. *Hepatology* 49(3):989-997.
149. Dolganiuc A, Petrasek J, Kodys K, Catalano D, Mandrekar P, Velayudham A, **Szabo G**. 2009. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. *Alcohol Clin Exp Res* 33(10):1704-1710.
150. Petrasek J, Nath B, Dolganiuc A, Hritz I, Kodys K, Catalano D, Kurt-Jones E, Mandrekar P, **Szabo G**. 2009. Hepatocyte-specific IRF3 signaling protects from alcohol-induced liver injury in mice through regulation of monocyte/macrophage-derived cytokines via type-I interferons. *Hepatology* 50(4, Suppl):869A.
151. Petrasek J, Dolganiuc A, Kurt-Jones E, **Szabo G**. 2009. Type I interferon induction and signaling protect from liver injury and granulomas through regulation of IL-1 receptor antagonist and dendritic cell recruitment in mice. *Gastroenterology* 136(5, Suppl 1):802A.
152. Bala S, Marcos M, **Szabo G**. 2009. Emerging Role of MicroRNAs in Liver Diseases. *World Journal of Gastroenterology*. 15(45):5633-5640.
153. Bala S, Tang A, **Szabo G**. 2009. Bcl-3 attenuates LPS-induced macrophage TNF $\alpha$  production through interaction with NF- $\kappa$ B p50 homodimers after acute alcohol exposure. *Cytokine*. 48 (1-2):124. Poster presented at Tri-Society Annual Conference 2009, Lisbon.

154. Marcos M\*, Bala S\*, Kodys K, Catalano D, Petrasek J, Mandrekar P, **Szabo G**. 2009. MicroRNA-155 in kupffer cells mediates increased TNF-alpha production in alcoholic liver disease. *Hepatology*. 50 (4, suppl):71a. (Oral Presentation at AASLD, Boston).
155. Bala S, Tang A, **Szabo G**. 2009. Acute alcohol induced LPS tolerance is mediated by Bcl-3 and p50. Oral presentation in AIRIG 2009 meeting, Chicago.
156. Szabo G, Bala S. 2010. Alcoholic liver disease and the gut-liver axis. *World J Gastroenterology*. 16(11):1321-29.